

QUESTION B. WHAT PERCENT OF YOUR PROFESSIONAL TIME IS SPENT IN PATIENT CARE?

	TOTAL
BASE	100
51 - 60 %	1 1.00
61 - 70 %	1 1.00
71 - 80 %	8 8.00
81 - 90 %	17 17.00
91 - 99 %	44 44.00
100 %	29 29.00
MEAN (INCLUDING NONE)	94.23
STANDARD DEVIATION (INCLUDING NONE)	7.46
STANDARD ERROR (INCLUDING NONE)	0.75
MEDIAN (INCLUDING NONE)	95
SIGMA	100

QUESTION C. HOW MANY YEARS HAVE YOU BEEN IN PRACTICE SINCE COMPLETING RESIDENCY OR FELLOWSHIP TRAINING?

	TOTAL
BASE	100
1	1 1.00
3	1 1.00
5	3 3.00
6	5 5.00
7	2 2.00
8	2 2.00
9	2 2.00
10	3 3.00
11	2 2.00
12	3 3.00
13	2 2.00
14	4 4.00
15	6 6.00
16	6 6.00
17	5 5.00
18	5 5.00
19	2 2.00
20	17 17.00
21	5 5.00
22	1 1.00
23	5 5.00
24	2 2.00



QUESTION C. HOW MANY YEARS HAVE YOU BEEN IN PRACTICE SINCE COMPLETING RESIDENCY OR FELLOWSHIP TRAINING?

	TOTAL
BASE	100
25	5 5.00
26	2 2.00
28	2 2.00
29	2 2.00
30	2 2.00
31	1 1.00
33	2 2.00
MEAN	17.44
STANDARD DEVIATION	7.08
STANDARD ERROR	0.71
MEDIAN	18
TOTAL	1744
SIGMA	100

(ROTATION A)  
QUESTION 2A1. IN THE LAST YEAR, ABOUT HOW MANY WOMEN HAVE YOU EVALUATED AND/OR TREATED WITH ADJUVANT SYSTEMIC THERAPY OF EARLY BREAST CANCER, THAT IS, INVASIVE AND NONINVASIVE WITH NO METASTASES?

	TOTAL
BASE	20
2	1 5.00
3	1 5.00
4	5 25.00
5	3 15.00
7	1 5.00
9	1 5.00
10	2 10.00
12	2 10.00
15	1 5.00
25	1 5.00
50	2 10.00
MEAN (INCLUDING NONE)	12.00
STANDARD DEVIATION (INCLUDING NONE)	14.06
STANDARD ERROR (INCLUDING NONE)	3.14
MEDIAN (INCLUDING NONE)	6
MEAN (EXCLUDING NONE)	12.00
STANDARD DEVIATION (EXCLUDING NONE)	14.06
STANDARD ERROR (EXCLUDING NONE)	3.14
MEDIAN (EXCLUDING NONE)	6
TOTAL	240
SIGMA	20

(ROTATION A)

QUESTION 2A2. WHICH REGIMEN OF CHEMOTHERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO #1 \*

ER-POSITIVE, HER2-NEGATIVE (0 BY IMMUNOHISTOCHEMISTRY)

ROTATION A

	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9	CASE 10	CASE 11	CASE 12
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)
AGE	43	43	43	43	33	33	65	65	65	65	77	77
TUMOR SIZE (CM)	2.2	2.2	2.2	0.8	2.2	0.8	2.2	2.2	2.2	0.8	2.2	0.8
NODES	10+	2+	NEG.	NEG.	10+	NEG.	10+	2+	NEG.	NEG.	10+	NEG.
BASE	20	20	20	20	20	20	20	20	20	20	20	20
AC-TAXOL	7 35.00DI KL	7 35.00DI KL	4 20.00DL	0 0.00	7 35.00DI KL	2 10.00	5 25.00DL	4 20.00DL	1 5.00	2 10.00	1 5.00	0 0.00
AC-TAXOTERE	7 35.00CD FIJL	5 25.00CDF JL	0 0.00	0 0.00	6 30.00CDF IJL	0 0.00	7 35.00CD FIJL	3 15.00	1 5.00	0 0.00	4 20.00CDF JL	0 0.00
FAC	3 15.00	3 15.00	4 20.00DJL	0 0.00	4 20.00DJL	1 5.00	3 15.00	4 20.00DJL	1 5.00	0 0.00	1 5.00	0 0.00
AC	0 0.00	1 5.00	9 45.00AB EGHJKL	5 25.00AEL	0 0.00	4 20.00AE L	2 10.00	3 15.00	9 45.00ABE GHJKL	1 5.00	2 10.00	0 0.00
CMF	0 0.00	0 0.00	2 10.00	0 0.00	0 0.00	1 5.00	0 0.00	2 10.00	2 10.00	1 5.00	4 20.00ABD EG	1 5.00
FEC (5FU, EPIRUBICIN, CYTOXAN)	2 10.00	2 10.00	0 0.00	0 0.00	2 10.00	0 0.00	1 5.00	1 5.00	0 0.00	0 0.00	1 5.00	0 0.00
SEC (5SU, EPIRUBICIN, CYTOXAN)	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00	0 0.00	0 0.00	1 5.00	0 0.00
FEC 100	1 5.00	1 5.00	1 5.00	0 0.00	1 5.00	0 0.00	1 5.00	1 5.00	0 0.00	1 5.00	1 5.00	0 0.00
NONE	0 0.00	0 0.00	0 0.00	15 75.00ABC EGHIK	0 0.00	12 60.00ABC EGHK	0 0.00	0 0.00	6 30.00AB CEGH	14 70.00AB CEGHK	4 20.00AB CEGH	18 90.00ABCEFGHIK
DON'T KNOW	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	1 5.00	1 5.00	1 5.00
SIGMA	20	20	20	20	20	20	20	20	20	20	20	20

Proportions/Means: All Columns Tested (5% risk level)

(ROTATION A)

QUESTION 2A3. WHICH REGIMEN OF ENDOCRINE THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO #1 \*

ER-POSITIVE, HER2-NEGATIVE (0 BY IMMUNOHISTOCHEMISTRY)

ROTATION A												
	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9	CASE 10	CASE 11	CASE 12
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)
AGE	43	43	43	43	33	33	65	65	65	65	77	77
TUMOR SIZE (CM)	2.2	2.2	2.2	0.8	2.2	0.8	2.2	2.2	2.2	0.8	2.2	0.8
NODES	10+	2+	NEG.	NEG.	10+	NEG.	10+	2+	NEG.	NEG.	10+	NEG.
BASE	20	20	20	20	20	20	20	20	20	20	20	20
TAMOXIFEN (NOLVADEX)	16 80.00JL	16 80.00JL	14 70.00JL	15 75.00JL	15 75.00JL	16 80.00JL	12 60.00	10 50.00	11 55.00	7 35.00	10 50.00	7 35.00
ANASTROZOLE (ARIMIDEX)	1 5.00	1 5.00	3 15.00	1 5.00	2 10.00	0 0.00	6 30.00AB DF	8 40.00AB DEF	7 35.00AB DF	8 40.00AB DEF	7 35.00AB DF	3 15.00
LETROZOLE (FEMARA)	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	2 10.00	2 10.00	2 10.00
EXEMESTANE (AROMASIN)	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00
LH-RH AGONIST/SURGICAL OR RADIATION OVARIAN ABLATION	1 5.00	0 0.00	0 0.00	0 0.00	2 10.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
LH-RH AGONIST/SURGICAL OR RADIATION OVARIAN ABLATION IF PATIENT IS STILL MENSTRUATING AFTER CHEMOTHERAPY	2 10.00	2 10.00	1 5.00	2 10.00	3 15.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
NONE	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	6 30.00ABCDEFGHIJK
DON'T KNOW	1 5.00	1 5.00	1 5.00	2 10.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	2 10.00	1 5.00	1 5.00
SIGMA	22	21	20	21	24	21	20	20	20	20	20	20

Proportions/Means: All Columns Tested (5% risk level)

(ROTATION A)

QUESTION 2A4. WHICH REGIMEN OF BIOLOGIC THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO #1 \*  
 ER-POSITIVE, HER2-NEGATIVE (0 BY IMMUNOHISTOCHEMISTRY)

ROTATION A													
	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9	CASE 10	CASE 11	CASE 12	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	
AGE	43	43	43	43	33	33	65	65	65	65	77	77	
TUMOR SIZE (CM)	2.2	2.2	2.2	0.8	2.2	0.8	2.2	2.2	2.2	0.8	2.2	0.8	
NODES	10+	2+	NEG.	NEG.	10+	NEG.	10+	2+	NEG.	NEG.	10+	NEG.	
BASE	20	20	20	20	20	20	20	20	20	20	20	20	
HERCEPTIN	2 10.00	1 5.00	0 0.00	1 5.00	2 10.00	1 5.00	2 10.00	1 5.00	1 5.00	0 0.00	1 5.00	0 0.00	
NONE	17 85.00	18 90.00	18 90.00	18 90.00	17 85.00	18 90.00	17 85.00	18 90.00	18 90.00	19 95.00	18 90.00	19 95.00	
DON'T KNOW	1 5.00	1 5.00	2 10.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	
SIGMA	20	20	20	20	20	20	20	20	20	20	20	20	

Proportions/Mean: All Columns Tested (5% risk level)



(ROTATION A)

QUESTION 2A5. WHICH REGIMEN OF CHEMOTHERAPY WOULD YOU PRESCRIBE FOR SCENARIO 2?

\* CLINICAL SCENARIO #2 \*  
 ER-POSITIVE, HER2 POSITIVE (3+ BY IMMUNOHISTOCHEMISTRY)

ROTATION A			
	CASE 1	CASE 2	CASE 3
	(A)	(B)	(C)
AGE	43	43	71
TUMOR SIZE (CM)	2.2	0.8	0.8
NODES	10+	NEG.	NEG.
BASE	20	20	20
AC-TAXOL	7 35.00BC	1 5.00	0 0.00
AC-TAXOTERE	6 30.00BC	1 5.00	0 0.00
FAC	4 20.00C	4 20.00C	0 0.00
AC	0 0.00	5 25.00AC	0 0.00
CMF	0 0.00	0 0.00	2 10.00
FEC (5FU, EPIRUBICIN, CYTOXAN)	2 10.00	0 0.00	0 0.00
FEC 100	1 5.00	0 0.00	0 0.00
NONE	0 0.00	9 45.00A	18 90.00AB
SIGMA	20	20	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION A)

QUESTION 2A6. WHICH REGIMEN OF ENDOCRINE THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 2?

\* CLINICAL SCENARIO #2 \*  
 ER-POSITIVE, HER2 POSITIVE (3+ BY IMMUNOHISTOCHEMISTRY)

ROTATION A			
	CASE 1	CASE 2	CASE 3
AGE	43	43	71
TUMOR SIZE (CM)	2.2	0.8	0.8
NODES	10+	NEG.	NEG.
	(A)	(B)	(C)
BASE	20	20	20
TAMOXIFEN (NOLVADEX)	16 80.00C	14 70.00	9 45.00
ANASTROZOLE (ARIMIDEX)	2 10.00	2 10.00	5 25.00
LETROZOLE (FEMARA)	1 5.00	1 5.00	2 10.00
LH-RH AGONIST/SURGICAL OR RADIATION OVARIAN ABLATION IF PATIENT IS STILL MENSTRUATING AFTER CHEMOTHERAPY	2 10.00	2 10.00	0 0.00
NONE	0 0.00	2 10.00	4 20.00A
SIGMA	21	21	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION A)

QUESTION 2A7. WHICH REGIMEN OF BIOLOGIC THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 2?

\* CLINICAL SCENARIO #2 \*  
 ER-POSITIVE, HER2 POSITIVE (3+ BY IMMUNOHISTOCHEMISTRY)

ROTATION A			
	CASE 1	CASE 2	CASE 3
AGE	43	43	71
TUMOR SIZE (CM)	2.2	0.8	0.8
NODES	10+	NEG.	NEG.
	(A)	(B)	(C)
BASE	20	20	20
HERCEPTIN	10 50.00BC	2 10.00	1 5.00
NONE	9 45.00	17 85.00A	19 95.00A
DON'T KNOW	1 5.00	1 5.00	0 0.00
SIGMA	20	20	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION A)

QUESTION 2A8. WHICH REGIMEN OF CHEMOTHERAPY WOULD YOU PRESCRIBE FOR SCENARIO 3?

\* CLINICAL SCENARIO #3 \*  
 ER-NEGATIVE, HER2 POSITIVE (3+ BY IMMUNOHISTOCHEMISTRY)

ROTATION A			
	CASE 1	CASE 2	CASE 3
	(A)	(B)	(C)
AGE	43	43	71
TUMOR SIZE (CM)	2.2	0.8	0.8
NODES	10+	NEG.	NEG.
BASE	20	20	20
AC-TAXOL	7 35.00BC	0 0.00	1 5.00
AC-TAXOTERE	6 30.00BC	1 5.00	0 0.00
FAC	4 20.00	4 20.00	1 5.00
AC	0 0.00	9 45.00A	5 25.00A
CMF	0 0.00	1 5.00	2 10.00
FEC (5FU, EPIRUBICIN, CYTOXAN)	2 10.00	0 0.00	0 0.00
ZELODA WITH TAXOTERE	0 0.00	0 0.00	1 5.00
FEC 100	0 0.00	1 5.00	0 0.00
NONE	1 5.00	4 20.00	9 45.00A
DON'T KNOW	0 0.00	0 0.00	1 5.00
SIGMA	20	20	20

Proportions/Means: All Columns Tested (5% risk level)

(ROTATION A)

QUESTION 2A9. WHICH REGIMEN OF ENDOCRINE THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 3?

\* CLINICAL SCENARIO #3 \*

ER-NEGATIVE, HER2 POSITIVE (3+ BY IMMUNOHISTOCHEMISTRY)

ROTATION A			
	CASE 1	CASE 2	CASE 3
	(A)	(B)	(C)
AGE	43	43	71
TUMOR SIZE (CM)	2.2	0.8	0.8
NODES	10+	NEG.	NEG.
BASE	20	20	20
TAMOXIFEN (NOLVADEX)	2 10.00	0 0.00	1 5.00
ANASTROZOLE (ARIMIDEX)	0 0.00	0 0.00	1 5.00
LH-RH AGONIST/SURGICAL OR RADIATION OVARIAN ABLATION IF PATIENT IS STILL MENSTRUATING AFTER CHEMOTHERAPY	2 10.00	2 10.00	0 0.00
NONE	15 75.00	17 85.00	17 85.00
DON'T KNOW	1 5.00	1 5.00	1 5.00
SIGMA	20	20	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION A)

QUESTION 2A10. WHICH REGIMEN OF BIOLOGIC THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 3?

\* CLINICAL SCENARIO #3 \*  
 ER-NEGATIVE, HER2 POSITIVE (3+ BY IMMUNOHISTOCHEMISTRY)

ROTATION A			
	CASE 1	CASE 2	CASE 3
	(A)	(B)	(C)
AGE	43	43	71
TUMOR SIZE (CM)	2.2	0.8	0.8
NODES	10+	NEG.	NEG.
BASE	20	20	20
HERCEPTIN	11 55.00BC	3 15.00	2 10.00
NONE	9 45.00	17 85.00A	18 90.00A
SIGMA	20	20	20

Proportions/Means: All Columns Tested (5% risk level)

(ROTATION A)

QUESTION 2A11. WHICH REGIMEN OF CHEMOTHERAPY WOULD YOU PRESCRIBE FOR SCENARIO 4?

\* CLINICAL SCENARIO #4 \*  
 ER-NEGATIVE, HER2 NEGATIVE (0 BY IMMUNOHISTOCHEMISTRY)

ROTATION A			
	CASE 1	CASE 2	CASE 3
	(A)	(B)	(C)
AGE	43	43	71
TUMOR SIZE (CM)	2.2	0.8	0.8
NODES	10+	NEG.	NEG.
BASE	20	20	20
AC-TAXOL	7 35.00BC	1 5.00	1 5.00
AC-TAXOTERE	6 30.00BC	1 5.00	0 0.00
FAC	4 20.00	4 20.00	1 5.00
AC	0 0.00	7 35.00A	3 15.00
CMF	0 0.00	2 10.00	5 25.00A
FEC (5FU, EPIRUBICIN, CYTOXAN)	2 10.00	0 0.00	0 0.00
ZELODA WITH TAXOTERE	0 0.00	0 0.00	1 5.00
NONE	1 5.00	5 25.00	7 35.00A
DON'T KNOW	0 0.00	0 0.00	2 10.00
SIGMA	20	20	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION A)

QUESTION 2A12. WHICH REGIMEN OF ENDOCRINE THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 4?

\* CLINICAL SCENARIO #4 \*  
 ER-NEGATIVE, HER2 NEGATIVE (0 BY IMMUNOHISTOCHEMISTRY)

ROTATION A			
	CASE 1	CASE 2	CASE 3
AGE	43	43	71
TUMOR SIZE (CM)	2.2	0.8	0.8
NODES	10+	NEG.	NEG.
	(A)	(B)	(C)
BASE	20	20	20
TAMOXIFEN (NOLVADEX)	1 5.00	0 0.00	0 0.00
LH-RH AGONIST/SURGICAL OR RADIATION OVARIAN ABLATION IF PATIENT IS STILL MENSTRUATING AFTER CHEMOTHERAPY	1 5.00	1 5.00	0 0.00
NONE	17 85.00	18 90.00	18 90.00
DON'T KNOW	1 5.00	1 5.00	2 10.00
SIGMA	20	20	20

Proportions/Mean: All Columns Tested (5% risk level)



(ROTATION A)

QUESTION 2A13. WHICH REGIMEN OF BIOLOGIC THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 4?

\* CLINICAL SCENARIO #4 \*  
 ER-NEGATIVE, HER2 NEGATIVE (0 BY IMMUNOHISTOCHEMISTRY)

ROTATION A			
	CASE 1	CASE 2	CASE 3
AGE	43	43	71
TUMOR SIZE (CM)	2.2	0.8	0.8
NODES	10+	NEG.	NEG.
	(A)	(B)	(C)
BASE	20	20	20
HERCEPTIN	0 0.00	1 5.00	0 0.00
NONE	19 95.00	18 90.00	19 95.00
DON'T KNOW	1 5.00	1 5.00	1 5.00
SIGMA	20	20	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION A)

QUESTION 2A14. WHEN YOU USE BOTH ADJUVANT CHEMOTHERAPY AND TAMOXIFEN, WHICH OF THE FOLLOWING BEST DESCRIBES THE USUAL SEQUENCE?

	TOTAL
BASE	20
FINISH CHEMOTHERAPY, THEN START TAMOXIFEN	17 85.00
START BOTH TOGETHER	2 10.00
CHEMOTHERAPY, RADIATION, THEN START TAMOXIFEN	1 5.00
SIGMA	20

(ROTATION A)

QUESTION 2A15. IF YOU WERE TO USE BOTH ADJUVANT CHEMOTHERAPY AND ANASTROZOLE, WHICH OF THE FOLLOWING BEST DESCRIBES  
WHAT YOU EXPECT WOULD BE THE USUAL SEQUENCE?

	TOTAL
BASE	20
FINISH CHEMOTHERAPY, THEN START TAMOXIFEN	17 85.00
START BOTH TOGETHER	2 10.00
WOULD NOT USE ANASTROZOLE	1 5.00
SIGMA	20

(ROTATION A)

QUESTION 2A16. WHICH OF THE FOLLOWING BEST DESCRIBES HOW YOU GENERALLY IDENTIFY A BREAST CANCER AS BEING ER-POSITIVE?

	TOTAL
BASE	20
ANY STAINING	10 50.00
STAINING ABOVE A SPECIFIC CUT-OFF AS DEFINED BY THE LAB DOING THE TEST	10 50.00
SIGMA	20

(ROTATION A)

QUESTION 2A17. WHICH OF THE FOLLOWING BEST DESCRIBES YOUR INTENDED USE IN THE NEAR FUTURE OF AN AROMATASE INHIBITOR AS ADJUVANT THERAPY?

	TOTAL
BASE	20
ANASTROZOLE OR LETROZOLE INTERCHANGEABLY	6 30.00
GENERALLY ANASTROZOLE, OCCASIONALLY LETROZOLE	6 30.00
ANASTROZOLE (ARIMIDEX)	5 25.00
LETROZOLE (FEMARA)	1 5.00
GENERALLY LETROZOLE, OCCASIONALLY ANASTROZOLE	1 5.00
NONE	1 5.00
SIGMA	20

(ROTATION A)

QUESTION 2A18. ABOUT HOW MANY TOTAL PATIENTS HAVE YOU TREATED WITH AN AROMATASE INHIBITOR AS ADJUVANT THERAPY?

	TOTAL
BASE	20
NONE	10
	50.00
1	3
	15.00
2	4
	20.00
5	2
	10.00
100	1
	5.00
MEAN	12.10
STANDARD DEVIATION	30.92
STANDARD ERROR	9.78
MEDIAN	2
TOTAL	121
SIGMA	20

(ROTATION B)

QUESTION 2B1. HOW MANY WOMEN HAVE BEEN TREATED WITH NEOADJUVANT CHEMOTHERAPY?

	TOTAL
BASE	20
1	1 5.00
2	4 20.00
3	1 5.00
5	4 20.00
6	1 5.00
7	1 5.00
8	1 5.00
9	1 5.00
10	3 15.00
15	1 5.00
20	1 5.00
50	1 5.00
MEAN (INCLUDING NONE)	8.85
STANDARD DEVIATION (INCLUDING NONE)	10.80
STANDARD ERROR (INCLUDING NONE)	2.41
MEDIAN (INCLUDING NONE)	6
MEAN (EXCLUDING NONE)	8.85
STANDARD DEVIATION (EXCLUDING NONE)	10.80
STANDARD ERROR (EXCLUDING NONE)	2.41
MEDIAN (EXCLUDING NONE)	6
TOTAL	177
SIGMA	20

(ROTATION B)

QUESTION 2B1A. HOW MANY WOMEN HAVE BEEN TREATED WITH NEOADJUVANT ENDOCRINE THERAPY?

	TOTAL
BASE	20
NONE	13
	65.00
1	1
	5.00
2	2
	10.00
3	1
	5.00
5	1
	5.00
9	1
	5.00
40	1
	5.00
MEAN (INCLUDING NONE)	3.10
STANDARD DEVIATION (INCLUDING NONE)	8.98
STANDARD ERROR (INCLUDING NONE)	2.01
MEAN (EXCLUDING NONE)	8.86
STANDARD DEVIATION (EXCLUDING NONE)	13.99
STANDARD ERROR (EXCLUDING NONE)	5.29
MEDIAN (EXCLUDING NONE)	3
TOTAL	62
SIGMA	20



(ROTATION B)

QUESTION 2B2. WHICH REGIMEN OF CHEMOTHERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* SCENARIO 1 \*

NEOADJUVANT THERAPY: ER-POSITIVE, HER 2-NEGATIVE (0 BY IMMUNOHISTOCHEMISTRY)

ROTATION B

	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9	CASE 10	CASE 11	CASE 12
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)
AGE	43	43	43	43	33	33	65	65	65	65	77	77
TUMOR SIZE (CM)	2.8	4.6	6.5	IBC	2.8	IBC	2.8	4.6	6.5	IBC	2.8	IBC
BASE	20	20	20	20	20	20	20	20	20	20	20	20
AC-TAXOL	0	2	2	2	0	2	0	0	2	3	0	0
	0.00	10.00	10.00	10.00	0.00	10.00	0.00	0.00	10.00	15.00	0.00	0.00
AC-TAXOTERE	2	5	5	4	4	4	0	4	4	2	0	2
	10.00	25.00GK	25.00GK	20.00GK	20.00GK	20.00GK	0.00	20.00GK	20.00GK	10.00	0.00	10.00
FAC	1	2	4	6	2	6	1	1	1	3	0	1
	5.00	10.00	20.00K	30.00AG HIKL	10.00	30.00AGH IKL	5.00	5.00	5.00	15.00	0.00	5.00
AC	8	9	8	6	7	6	8	8	8	9	5	7
	40.00	45.00	40.00	30.00	35.00	30.00	40.00	40.00	40.00	45.00	25.00	35.00
CMF	0	0	0	0	0	0	2	1	1	1	2	2
	0.00	0.00	0.00	0.00	0.00	0.00	10.00	5.00	5.00	5.00	10.00	10.00
TAXOL	1	1	2	2	2	2	1	1	2	2	0	0
	5.00	5.00	10.00	10.00	10.00	10.00	5.00	5.00	10.00	10.00	0.00	0.00
TAXOTERE	0	0	0	0	0	0	0	0	0	0	0	1
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.00
FEC	1	0	0	0	1	0	1	0	0	0	0	0
	5.00	0.00	0.00	0.00	5.00	0.00	5.00	0.00	0.00	0.00	0.00	0.00
AC - ADRIAMYCIN	0	1	0	0	0	0	0	0	0	0	0	0
	0.00	5.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
A - TAXOTERE	0	0	0	1	0	1	0	0	0	1	0	0
	0.00	0.00	0.00	5.00	0.00	5.00	0.00	0.00	0.00	5.00	0.00	0.00
CMF AND ARIMIDEX	0	0	0	0	0	0	0	0	0	0	1	0
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.00	0.00
FEC AND ARIMIDEX	0	0	0	0	0	0	0	0	0	0	0	1
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.00
NONE	6	0	0	0	5	0	7	5	2	0	12	6
	30.00BCD FJ	0.00	0.00	0.00	25.00BCD FJ	0.00	35.00BC DFJ	25.00BC DFJ	10.00	0.00	60.00BC DEFHIJ	30.00BCDFJ
DON'T KNOW	1	0	0	0	0	0	0	0	0	0	0	0
	5.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SIGMA	20	20	21	21	21	21	20	20	20	21	20	20

Proportions/Means: All Columns Tested (5% risk level)

(ROTATION B)

QUESTION 2B3. WHICH REGIMEN OF ENDOCRINE THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* SCENARIO 1 \*

NEOADJUVANT THERAPY: ER-POSITIVE, HER 2-NEGATIVE (0 BY IMMUNOHISTOCHEMISTRY)

ROTATION B

	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9	CASE 10	CASE 11	CASE 12
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)
AGE	43	43	43	43	33	33	65	65	65	65	77	77
TUMOR SIZE (CM)	2.8	4.6	6.5	IBC	2.8	IBC	2.8	4.6	6.5	IBC	2.8	IBC
BASE	20	20	20	20	20	20	20	20	20	20	20	20
TAMOXIFEN (NOLVADEX)	5 25.00	4 20.00	4 20.00	4 20.00	4 20.00	4 20.00	4 20.00	4 20.00	4 20.00	4 20.00	3 15.00	5 25.00
ANASTROZOLE (ARIMIDEX)	3 15.00	5 25.00	5 25.00	6 30.00	5 25.00	6 30.00	5 25.00	4 20.00	5 25.00	5 25.00	9 45.00A	8 40.00
LETROZOLE (FEMARA)	1 5.00	1 5.00	2 10.00	1 5.00	0 0.00	0 0.00	1 5.00	1 5.00	2 10.00	3 15.00	0 0.00	2 10.00
EXEMESTANE (AROMASIN)	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00	0 0.00	0 0.00	1 5.00
LH-RH AGONIST/SURGICAL OR RADIATION OVARIAN ABLATION	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	2 10.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
NONE	10 50.00	10 50.00	9 45.00	8 40.00	11 55.00L	9 45.00	10 50.00	10 50.00	8 40.00	8 40.00	8 40.00	4 20.00
DON'T KNOW	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
SIGMA	21	21	21	20	21	21	20	20	20	20	20	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION B)

QUESTION 2B4. WHICH REGIMEN OF BIOLOGIC THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* SCENARIO 1 \*

NEOADJUVANT THERAPY: ER-POSITIVE, HER 2-NEGATIVE (0 BY IMMUNOHISTOCHEMISTRY)

ROTATION C

	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9	CASE 10	CASE 11	CASE 12
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)
AGE	43	43	43	43	33	33	65	65	65	65	77	77
TUMOR SIZE (CM)	2.8	4.6	6.5	IBC	2.8	IBC	2.8	4.6	6.5	IBC	2.8	IBC
BASE	20	20	20	20	20	20	20	20	20	20	20	20
HERCEPTIN	1 5.00	1 5.00	1 5.00	1 5.00	2 10.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	0 0.00	0 0.00
NONE	19 95.00	19 95.00	19 95.00	18 90.00	18 90.00	18 90.00	19 95.00	19 95.00	19 95.00	18 90.00	20 100.00	20 100.00
DON'T KNOW	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00
SIGMA	20	20	20	20	20	20	20	20	20	20	20	20

Proportions/Means: All Columns Tested (5% risk level)

(ROTATION B)

QUESTION 2B5. WHICH REGIMEN OF CHEMOTHERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* SCENARIO 1 \*

POST OP THERAPY: ER-POSITIVE, HER 2-NEGATIVE (0 BY IMMUNOHISTOCHEMISTRY)

ROTATION B

	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9	CASE 10	CASE 11	CASE 12
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)
AGE	43	43	43	43	33	33	65	65	65	65	77	77
TUMOR SIZE (CM)	2.8	4.6	6.5	IBC	2.8	IBC	2.8	4.6	6.5	IBC	2.8	IBC
BASE	20	20	20	20	20	20	20	20	20	20	20	20
AC-TAXOL	1 5.00	2 10.00	3 15.00	4 20.00	1 5.00	3 15.00	1 5.00	1 5.00	2 10.00	2 10.00	1 5.00	1 5.00
AC-TAXOTERE	0 0.00	3 15.00	4 20.00A	4 20.00A	3 15.00	4 20.00A	1 5.00	2 10.00	2 10.00	2 10.00	1 5.00	2 10.00
FAC	2 10.00	3 15.00	4 20.00	2 10.00	3 15.00	2 10.00	1 5.00	1 5.00	2 10.00	2 10.00	1 5.00	1 5.00
AC	10 50.00CD HKL	4 20.00	2 10.00	3 15.00	7 35.00K	4 20.00	7 35.00K	3 15.00	4 20.00	5 25.00	1 5.00	3 15.00
CMF	0 0.00	1 5.00	1 5.00	1 5.00	0 0.00	1 5.00	3 15.00	4 20.00AE	2 10.00	3 15.00	2 10.00	3 15.00
TAXOL	3 15.00	4 20.00	4 20.00	5 25.00	2 10.00	5 25.00	2 10.00	3 15.00	3 15.00	4 20.00	1 5.00	2 10.00
TAXOTERE	2 10.00	2 10.00	2 10.00	1 5.00	2 10.00	1 5.00	2 10.00	2 10.00	3 15.00	1 5.00	2 10.00	2 10.00
FEC	1 5.00	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
A - TAXOTERE	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00
NONE	1 5.00	2 10.00	1 5.00	0 0.00	1 5.00	0 0.00	3 15.00	4 20.00DF J	2 10.00	0 0.00	10 50.00AB CDEFGIJ	5 25.00DFJ
DON'T KNOW	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00
SIGMA	21	21	21	21	20	21	20	20	20	20	20	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION B)

QUESTION 2B6. WHICH REGIMEN OF ENDOCRINE THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* SCENARIO 1 \*

POST OP THERAPY: ER-POSITIVE, HER 2-NEGATIVE (0 BY IMMUNOHISTOCHEMISTRY)

ROTATION B

	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9	CASE 10	CASE 11	CASE 12
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)
AGE	43	43	43	43	33	33	65	65	65	65	77	77
TUMOR SIZE (CM)	2.8	4.6	6.5	IBC	2.8	IBC	2.8	4.6	6.5	IBC	2.8	IBC
BASE	20	20	20	20	20	20	20	20	20	20	20	20
TAMOXIFEN (NOLVADEX)	10 50.00	10 50.00	10 50.00	9 45.00	9 45.00	8 40.00	9 45.00	9 45.00	9 45.00	9 45.00	9 45.00	8 40.00
ANASTROZOLE (ARIMIDEX)	8 40.00	8 40.00	8 40.00	9 45.00	7 35.00	9 45.00	9 45.00	10 50.00	9 45.00	9 45.00	10 50.00	10 50.00
LETROZOLE (FEMARA)	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00	0 0.00	1 5.00
LH-RH AGONIST/SURGICAL OR RADIATION OVARIAN ABLATION	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	2 10.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
NONE	2 10.00	2 10.00	2 10.00	2 10.00	3 15.00	3 15.00	2 10.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00
DON'T KNOW	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
SIGMA	21	21	21	21	21	22	20	20	20	20	20	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION B)

QUESTION 2B7. WHICH REGIMEN OF BIOLOGIC THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* SCENARIO 1 \*

POST OP THERAPY: ER-POSITIVE, HER 2-NEGATIVE (0 BY IMMUNOHISTOCHEMISTRY)

ROTATION C

	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9	CASE 10	CASE 11	CASE 12
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)
AGE	43	43	43	43	33	33	65	65	65	65	77	77
TUMOR SIZE (CM)	2.8	4.6	6.5	IBC	2.8	IBC	2.8	4.6	6.5	IBC	2.8	IBC
BASE	20	20	20	20	20	20	20	20	20	20	20	20
HERCEPTIN	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00
NONE	20 100.00	20 100.00	20 100.00	19 95.00	20 100.00	18 90.00	20 100.00	20 100.00	20 100.00	19 95.00	19 95.00	20 100.00
DON'T KNOW	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00
SIGMA	20	20	20	20	20	20	20	20	20	20	20	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION B)

QUESTION 2B8. WHICH REGIMEN OF CHEMOTHERAPY WOULD YOU PRESCRIBE FOR SCENARIO 2?

\* SCENARIO 2 \*

NEOADJUVANT THERAPY: ER-NEGATIVE, HER 2-POSITIVE (3+ BY IMMUNOHISTOCHEMISTRY)

ROTATION B				
	CASE 1	CASE 2	CASE 3	CASE 4
AGE	43	43	43	71
TUMOR SIZE (CM)	2.2	6.5	IBC	IBC
	(A)	(B)	(C)	(D)
BASE	20	20	20	20
AC-TAXOL	1 5.00	2 10.00	3 15.00	1 5.00
AC-TAXOTERE	2 10.00	5 25.00	5 25.00	2 10.00
FAC	1 5.00	3 15.00	3 15.00	3 15.00
AC	7 35.00	7 35.00	5 25.00	8 40.00
CMF	0 0.00	0 0.00	0 0.00	1 5.00
TAXOL	1 5.00	1 5.00	4 20.00D	0 0.00
ADRIAMYCIN	1 5.00	1 5.00	0 0.00	1 5.00
FEC	2 10.00	0 0.00	0 0.00	0 0.00
GEMCITABINE	0 0.00	1 5.00	1 5.00	1 5.00
NONE	5 25.00BC	0 0.00	0 0.00	3 15.00
SIGMA	20	20	21	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION B)

QUESTION 2B9. WHICH REGIMEN OF ENDOCRINE THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 2?

\* SCENARIO 2 \*

NEOADJUVANT THERAPY: ER-NEGATIVE, HER 2-POSITIVE (3+ BY IMMUNOHISTOCHEMISTRY)

ROTATION B				
	CASE 1	CASE 2	CASE 3	CASE 4
	(A)	(B)	(C)	(D)
AGE	43	43	43	71
TUMOR SIZE (CM)	2.2	6.5	IBC	IBC
BASE	20	20	20	20
TAMOXIFEN (NOLVADEX)	2 10.00	2 10.00	2 10.00	1 5.00
ANASTROZOLE (ARIMIDEX)	0 0.00	0 0.00	0 0.00	1 5.00
LETROZOLE (FEMARA)	2 10.00	2 10.00	2 10.00	2 10.00
EXEMESTANE (AROMASIN)	0 0.00	0 0.00	0 0.00	1 5.00
LH-RH AGONIST/SURGICAL OR RADIATION OVARIAN ABLATION	1 5.00	1 5.00	1 5.00	0 0.00
NONE	16 80.00	16 80.00	16 80.00	15 75.00
SIGMA	21	21	21	20

Proportions/Mean: All Columns Tested (5% risk level)



(ROTATION B)

QUESTION 2B10. WHICH REGIMEN OF BIOLOGIC THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 2?

\* SCENARIO 2 \*

NEOADJUVANT THERAPY: ER-NEGATIVE, HER 2-POSITIVE (3+ BY IMMUNOHISTOCHEMISTRY)

ROTATION B

	CASE 1	CASE 2	CASE 3	CASE 4
	(A)	(B)	(C)	(D)
AGE	43	43	43	71
TUMOR SIZE (CM)	2.2	6.5	IBC	IBC

BASE	20	20	20	20
HERCEPTIN	7 35.00	12 60.00	13 65.00	12 60.00
NONE	13 65.00	8 40.00	7 35.00	8 40.00
SIGMA	20	20	20	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION B)

QUESTION 2B11. WHICH REGIMEN OF CHEMOTHERAPY WOULD YOU PRESCRIBE FOR SCENARIO 2?

\* SCENARIO 2 \*

POST OP THERAPY: ER-NEGATIVE, HER 2-POSITIVE (3+ BY IMMUNOHISTOCHEMISTRY)

ROTATION B				
	CASE 1	CASE 2	CASE 3	CASE 4
	(A)	(B)	(C)	(D)
AGE	43	43	43	71
TUMOR SIZE (CM)	2.8	6.5	IBC	IBC
BASE	20	20	20	20
AC-TAXOL	2 10.00	4 20.00D	2 10.00	0 0.00
AC-TAXOTERE	1 5.00	3 15.00	4 20.00	1 5.00
FAC	2 10.00	3 15.00	2 10.00	1 5.00
AC	6 30.00BC	0 0.00	0 0.00	4 20.00BC
CMF	0 0.00	0 0.00	0 0.00	1 5.00
TAXOL	4 20.00	6 30.00	8 40.00	6 30.00
TAXOTERE	1 5.00	2 10.00	2 10.00	3 15.00
ADRIAMYCIN	1 5.00	1 5.00	1 5.00	1 5.00
FEC	2 10.00	0 0.00	0 0.00	0 0.00
GEMCITABINE	0 0.00	0 0.00	1 5.00	1 5.00
NONE	1 5.00	1 5.00	0 0.00	2 10.00
SIGMA	20	20	20	20

Proportions/Means: All Columns Tested (5% risk level)

(ROTATION B)

QUESTION 2B12. WHICH REGIMEN OF ENDOCRINE THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 2?

\* SCENARIO 2 \*

POST OP THERAPY: ER-NEGATIVE, HER 2-POSITIVE (3+ BY IMMUNOHISTOCHEMISTRY)

ROTATION B				
	CASE 1	CASE 2	CASE 3	CASE 4
	(A)	(B)	(C)	(D)
AGE	43	43	43	71
TUMOR SIZE (CM)	2.8	6.5	IBC	IBC
BASE	20	20	20	20
TAMOXIFEN (NOLVADEX)	2 10.00	2 10.00	2 10.00	1 5.00
ANASTROZOLE (ARIMIDEX)	1 5.00	1 5.00	1 5.00	4 20.00
LETROZOLE (FEMARA)	1 5.00	1 5.00	1 5.00	2 10.00
EXEMESTANE (AROMASIN)	0 0.00	1 5.00	0 0.00	0 0.00
LH-RH AGONIST/SURGICAL OR RADIATION OVARIAN ABLATION	1 5.00	1 5.00	1 5.00	0 0.00
NONE	15 75.00	14 70.00	15 75.00	12 60.00
DON'T KNOW	1 5.00	1 5.00	1 5.00	1 5.00
SIGMA	21	21	21	20

Proportions/Means: All Columns Tested (5% risk level)

(ROTATION B)

QUESTION 2B13. WHICH REGIMEN OF BIOLOGIC THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 2?

\* SCENARIO 2 \*

POST OP THERAPY: ER-NEGATIVE, HER 2-POSITIVE (3+ BY IMMUNOHISTOCHEMISTRY)

ROTATION B				
	CASE 1	CASE 2	CASE 3	CASE 4
	(A)	(B)	(C)	(D)
AGE	43	43	43	71
TUMOR SIZE (CM)	2.8	6.5	IBC	IBC
BASE	20	20	20	20
HERCEPTIN	5 25.00	7 35.00	11 55.00	9 45.00
NONE	15 75.00	13 65.00	9 45.00	10 50.00
DON'T KNOW	0 0.00	0 0.00	0 0.00	1 5.00
SIGMA	20	20	20	20

Proportions/Means: All Columns Tested (5% risk level)

(ROTATION B)

QUESTION 2B14. IN ABOUT HOW MANY PATIENTS, IF ANY, HAVE YOU USED AN AROMATASE INHIBITOR AS NEOADJUVANT THERAPY?

	TOTAL
BASE	20
NONE	14 70.00
1	1 5.00
2	1 5.00
3	1 5.00
5	2 10.00
40	1 5.00
MEAN (INCLUDING NONE)	2.80
STANDARD DEVIATION (INCLUDING NONE)	8.91
STANDARD ERROR (INCLUDING NONE)	1.99
MEAN (EXCLUDING NONE)	9.33
STANDARD DEVIATION (EXCLUDING NONE)	15.11
STANDARD ERROR (EXCLUDING NONE)	6.17
MEDIAN (EXCLUDING NONE)	4
TOTAL	56
SIGMA	20

(ROTATION B)

QUESTION 2B15. IF YOU FIND THE ATAC TRIAL DATA TO BE CREDIBLE AND AS PRESENTED ABOVE WHICH OF THE FOLLOWING BEST DESCRIBES HOW YOU THINK IT WILL CHANGE YOUR USE OF NEOADJUVANT AROMATASE INHIBITORS, IF AT ALL?

	TOTAL
BASE	20
I WILL USE MY AI'S SLIGHTLY MORE AS NEOADJUVANT THERAPY	11 55.00
I WILL USE MY AI'S QUITE A BIT MORE AS NEOADJUVANT THERAPY	5 25.00
NO IMPACT, I WILL CONTINUE MY CURRENT PRACTICE	3 15.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION B)

QUESTION 2B16. IN ABOUT HOW MANY PATIENTS HAVE YOU USED HERCEPTIN AS NEOADJUVANT THERAPY?

	TOTAL
BASE	20
NONE	13
	65.00
1	1
	5.00
2	3
	15.00
3	1
	5.00
4	1
	5.00
50	1
	5.00
MEAN (INCLUDING NONE)	3.20
STANDARD DEVIATION (INCLUDING NONE)	11.08
STANDARD ERROR (INCLUDING NONE)	2.48
MEAN (EXCLUDING NONE)	9.14
STANDARD DEVIATION (EXCLUDING NONE)	18.04
STANDARD ERROR (EXCLUDING NONE)	6.82
MEDIAN (EXCLUDING NONE)	2
TOTAL	64
SIGMA	20

(ROTATION C)

QUESTION 2C1. IN THE LAST YEAR, ABOUT HOW MANY WOMEN HAVE YOU EVALUATED AND/OR TREATED WITH METASTATIC BREAST CANCER?

	TOTAL
BASE	20
20	2 10.00
24	1 5.00
35	2 10.00
36	1 5.00
40	1 5.00
50	4 20.00
60	1 5.00
70	1 5.00
80	2 10.00
100	2 10.00
120	1 5.00
125	1 5.00
1500	1 5.00
MEAN (INCLUDING NONE)	132.25
STANDARD DEVIATION (INCLUDING NONE)	323.49
STANDARD ERROR (INCLUDING NONE)	72.33
MEDIAN (INCLUDING NONE)	50
MEAN (EXCLUDING NONE)	132.25
STANDARD DEVIATION (EXCLUDING NONE)	323.49
STANDARD ERROR (EXCLUDING NONE)	72.33
MEDIAN (EXCLUDING NONE)	50
TOTAL	2645
SIGMA	20



(ROTATION C)

QUESTION 2C1A. ABOUT HOW MANY HAD HER2 STATUS DETERMINED?

	TOTAL
BASE	20
12	1 5.00
15	1 5.00
20	1 5.00
24	1 5.00
25	1 5.00
35	2 10.00
40	1 5.00
50	5 25.00
55	1 5.00
60	2 10.00
72	1 5.00
78	1 5.00
100	1 5.00
1500	1 5.00
MEAN (INCLUDING NONE)	119.05
STANDARD DEVIATION (INCLUDING NONE)	325.78
STANDARD ERROR (INCLUDING NONE)	72.85
MEDIAN (INCLUDING NONE)	50
MEAN (EXCLUDING NONE)	119.05
STANDARD DEVIATION (EXCLUDING NONE)	325.78
STANDARD ERROR (EXCLUDING NONE)	72.85
MEDIAN (EXCLUDING NONE)	50
TOTAL	2381
SIGMA	20

(ROTATION C AND IF "SOME WOMEN HAD HER2 STATUS" IN QUESTION 2C1A)  
QUESTION 2C1B. ABOUT HOW MANY WERE HER2 POSITIVE?

	TOTAL
BASE	20
4	2 10.00
5	2 10.00
6	1 5.00
7	2 10.00
8	1 5.00
10	3 15.00
13	1 5.00
15	3 15.00
20	1 5.00
30	1 5.00
36	1 5.00
40	1 5.00
150	1 5.00
MEAN (INCLUDING NONE)	20.50
STANDARD DEVIATION (INCLUDING NONE)	32.21
STANDARD ERROR (INCLUDING NONE)	7.20
MEDIAN (INCLUDING NONE)	10
MEAN (EXCLUDING NONE)	20.50
STANDARD DEVIATION (EXCLUDING NONE)	32.21
STANDARD ERROR (EXCLUDING NONE)	7.20
MEDIAN (EXCLUDING NONE)	10
TOTAL	410
SIGMA	20

(ROTATION C)

QUESTION 2C2. WHICH REGIMEN OF CHEMOTHERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC, ER-POSITIVE, HER 2-NEGATIVE (0 BY INNUMOHISTOCHEMISTRY)

ROTATION C									
	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9
AGE	43	43	43	43	43	43	43	43	43
DISEASE SITE	BONE	BONE	LIVER,	LIVER,	BONE	BONE	BONE	LIVER,	LIVER,
AD	NONE	NONE	NONE	NONE	AD CMFA	AD AC	AD AC-T	AD AC	AD AC-T
CLINICAL CONDITION	ASYMP	MULTI SITES OF MOD PAIN	ASYMP	VERY ILL	SYMP	ASYMP	ASYMP	VERY ILL	VERY ILL
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
BASE	20	20	20	20	20	20	20	20	20
PACLITAXEL	1 5.00	1 5.00	2 10.00	3 15.00	4 20.00G	1 5.00	0 0.00	4 20.00G	2 10.00
DOCETAXEL	4 20.00	5 25.00	9 45.00G	10 50.00G	7 35.00	7 35.00	3 15.00	8 40.00	6 30.00
DOXORUBICIN	3 15.00	3 15.00	3 15.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
EPIRUBICIN	1 5.00	1 5.00	0 0.00	2 10.00	2 10.00	0 0.00	0 0.00	0 0.00	0 0.00
CAPECITABINE	0 0.00	1 5.00	0 0.00	2 10.00	0 0.00	1 5.00	1 5.00	2 10.00	5 25.00ACE
VINORELBINE	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00	3 15.00	3 15.00	4 20.00ABCD
GEMCITABINE	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00	1 5.00	2 10.00
DOCETAXEL AND DOXORUBICIN IN COMBINATION	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
DOCETAXEL AND CAPECITABINE IN COMBINATION	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00
ZOMETA	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
CUTPXAN/ CYCLOPHOSPHAMIDE	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
CARBOPLATIN	0 0.00	0 0.00	1 5.00	0 0.00	1 5.00	0 0.00	0 0.00	1 5.00	1 5.00
XELODA	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00
ZOMETA AND AREDIA IN COMBINATION	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00	0 0.00	0 0.00
PREDNISONE	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00
VINORELBINE AND GEMCITABINE IN COMBINATION	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00

(ROTATION C)  
 QUESTION 2C2. WHICH REGIMEN OF CHEMOTHERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC, ER-POSITIVE, HER 2-NEGATIVE (0 BY INNUMOHISTOCHEMISTRY)

ROTATION C									
	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9
AGE	43	43	43	43	43	43	43	43	43
DISEASE SITE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE	BONE	BONE	LIVER, LUNG	LIVER, LUNG
AD	NONE	NONE	NONE	NONE	AD CMFA	AD AC	AD AC-T	AD AC	AD AC-T
CLINICAL CONDITION	ASYMP	MULTI SITES OF MOD PAIN	ASYMP	VERY ILL	SYMP	ASYMP	ASYMP	VERY ILL	VERY ILL
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
BASE	20	20	20	20	20	20	20	20	20
NONE	13	10	7	3	8	11	14	4	4
	65.00DH I	50.00D	35.00	15.00	40.00	55.00DH I	70.00CD HI	20.00	20.00
SIGMA	22	23	23	23	23	23	23	26	28

Proportions/Means: All Columns Tested (5% risk level)

(ROTATION C)

QUESTION 2C2. WHICH REGIMEN OF CHEMOTHERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC, ER-POSITIVE, HER 2-NEGATIVE (0 BY INNUMOHISTOCHEMISTRY)

ROTATION C										
	CASE 10	CASE 11	CASE 12	CASE 13	CASE 14	CASE 15	CASE 16	CASE 17	CASE 18	CASE 19
AGE	63	63	63	63	63	63	63	63	63	78
DISEASE SITE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE
AD CLINICAL CONDITION	NONE	NONE	NONE	NONE	AD CMF	AD AC	AD AC-T	AD AC	AD AC-T	NONE
	ASYP	MULTI SITES OF MOD PAIN	ASYMP	VERY ILL	ASYMP	ASYMP	ASYMP	VERY ILL	VERY ILL	ASYMP
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)
BASE	20	20	20	20	20	20	20	20	20	20
PACLITAXEL	2 10.00	2 10.00	3 15.00	4 20.00GJ	1 5.00	1 5.00	0 0.00	4 20.00GJ	2 10.00	0 0.00
DOCETAXEL	0 0.00	2 10.00	3 15.00	8 40.00ABJ	3 15.00	3 15.00	3 15.00	11 55.00ABC EFGJ	8 40.00ABJ	1 5.00
DOXORUBICIN	0 0.00	0 0.00	2 10.00	2 10.00	2 10.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
EPIRUBICIN	1 5.00	1 5.00	1 5.00	0 0.00	1 5.00	0 0.00	0 0.00	1 5.00	1 5.00	0 0.00
CAPECITABINE	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00	0 0.00	1 5.00	1 5.00	3 15.00	0 0.00
VINORELBINE	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	3 15.00	1 5.00	5 25.00ABCD EFJ	0 0.00
GEMCITABINE	0 0.00	1 5.00	0 0.00	2 10.00	1 5.00	1 5.00	1 5.00	1 5.00	2 10.00	0 0.00
CARBOPLATIN	0 0.00	0 0.00	1 5.00	1 5.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00	0 0.00
XELODA	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00	0 0.00
ZOMETA AND AREDIA IN COMBINATION	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00	0 0.00	0 0.00	0 0.00
PREDNISONE	1 5.00	1 5.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00
VINORELBINE AND GEMCITABINE IN COMBINATION	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00
AREDIA	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
CMF - CYTOXAN, METHOTREXATE, 5FU (FLUOROURACIL) IN COMBINATION	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00
TAXOTERE	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00

(ROTATION C)  
 QUESTION 2C2. WHICH REGIMEN OF CHEMOTHERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC, ER-POSITIVE, HER 2-NEGATIVE (0 BY INNUMOHISTOCHEMISTRY)

ROTATION C										
	CASE 10	CASE 11	CASE 12	CASE 13	CASE 14	CASE 15	CASE 16	CASE 17	CASE 18	CASE 19
AGE	63	63	63	63	63	63	63	63	63	78
DISEASE SITE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE
AD	NONE	NONE	NONE	NONE	AD CMF	AD AC	AD AC-T	AD AC	AD AC-T	NONE
CLINICAL CONDITION	ASYMP	MULTI SITES OF MOD PAIN	ASYMP	VERY ILL	ASYMP	ASYMP	ASYMP	VERY ILL	VERY ILL	ASYMP
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)
BASE	20	20	20	20	20	20	20	20	20	20
NONE	16 80.00DHI	14 70.00DHI	11 55.00HI	5 25.00	13 65.00DHI	14 70.00DHI	14 70.00DHI	3 15.00	3 15.00	18 90.00CDHI
DON'T KNOW	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00
SIGMA	21	22	22	26	22	21	23	26	27	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION C)

QUESTION 2C3. WHICH REGIMEN OF ENDOCRINE THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC, ER-POSITIVE, HER 2-NEGATIVE (0 BY INNUMOHISTOCHEMISTRY)

ROTATION C									
	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9
AGE	43	43	43	43	43	43	43	43	43
DISEASE SITE	BONE	BONE	LIVER,	LIVER,	BONE	BONE	BONE	LIVER,	LIVER,
AD	NONE	NONE	LUNG	LUNG	AD CMFA	AD AC	AD AC-T	LUNG	LUNG
CLINICAL CONDITION	ASYMP	SITES OF MOD PAIN	ASYMP	VERY ILL	SYMP	ASYMP	ASYMP	VERY ILL	VERY ILL
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
BASE	20	20	20	20	20	20	20	20	20
TAMOXIFEN (NOLVADEX)	9 45.00CD HI	7 35.00	3 15.00	3 15.00	6 30.00	8 40.00I	6 30.00	3 15.00	2 10.00
ANASTROZOLE (ARIMIDEX)	2 10.00	2 10.00	1 5.00	1 5.00	1 5.00	1 5.00	3 15.00	1 5.00	2 10.00
LETROZOLE (FEMARA)	5 25.00	6 30.00	6 30.00	4 20.00	6 30.00	7 35.00	8 40.00	4 20.00	4 20.00
EXEMESTANT (AROMASIN)	1 5.00	1 5.00	2 10.00	1 5.00	2 10.00	2 10.00	1 5.00	1 5.00	1 5.00
LH-RH AGONIST/SURGICAL OR RADIATION OVARIAN ABLATION	4 20.00	4 20.00	3 15.00	2 10.00	2 10.00	2 10.00	3 15.00	2 10.00	2 10.00
LH-RH AGONIST/SURGICAL OR RADIATION OVARIAN ABLATION IF PATIENT IS STILL MENSTRUATING AFTER CHEMOTHERAPY	1 5.00	1 5.00	0 0.00	0 0.00	3 15.00	3 15.00	3 15.00	0 0.00	0 0.00
AREDIA	2 10.00	2 10.00	0 0.00	1 5.00	2 10.00	2 10.00	2 10.00	0 0.00	0 0.00
ZOMETA	1 5.00	1 5.00	0 0.00	0 0.00	1 5.00	1 5.00	1 5.00	0 0.00	0 0.00
LETROZOLE AND LH-RH AGONIST/ SURGICAL OR RADIATION OVARIAN ABLATION	0 0.00	1 5.00	1 5.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00
RADIATION THERAPY	0 0.00	1 5.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00
NONE	3 15.00	3 15.00	9 45.00AB EFG	9 45.00AB EFG	3 15.00	3 15.00	1 5.00	11 55.00AB EFG	11 55.00ABEFG
SIGMA	28	29	25	21	28	29	28	22	22

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION C)

QUESTION 2C3. WHICH REGIMEN OF ENDOCRINE THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*

METASTATIC, ER-POSITIVE, HER 2-NEGATIVE (0 BY INNUMOHISTOCHEMISTRY)

ROTATION C										
	CASE 10	CASE 11	CASE 12	CASE 13	CASE 14	CASE 15	CASE 16	CASE 17	CASE 18	CASE 19
AGE	63	63	63	63	63	63	63	63	63	78
DISEASE SITE	BONE	BONE	LIVER,	LIVER,	BONE	BONE	BONE	LIVER,	LIVER,	BONE
AD	NONE	NONE	LUNG	LUNG	AD CMF	AD AC	AD AC-T	LUNG	LUNG	BONE
CLINICAL CONDITION	ASYP	MULTI SITES OF MOD PAIN	ASYP	VERY ILL	ASYP	ASYP	ASYP	VERY ILL	VERY ILL	ASYP
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)
BASE	20	20	20	20	20	20	20	20	20	20
TAMOXIFEN (NOLVADEX)	6 30.00I	4 20.00	2 10.00	2 10.00	4 20.00	4 20.00	3 15.00	2 10.00	1 5.00	4 20.00
ANASTROZOLE (ARIMIDEX)	5 25.00	5 25.00	3 15.00	3 15.00	4 20.00	3 15.00	4 20.00	2 10.00	3 15.00	5 25.00
LETROZOLE (FEMARA)	6 30.00	8 40.00	8 40.00	5 25.00	8 40.00	8 40.00	9 45.00	6 30.00	6 30.00	7 35.00
EXEMESTANT (AROMASIN)	1 5.00	2 10.00	2 10.00	1 5.00	1 5.00	2 10.00	2 10.00	2 10.00	1 5.00	2 10.00
ARELIA	2 10.00	2 10.00	0 0.00	0 0.00	1 5.00	1 5.00	2 10.00	0 0.00	0 0.00	2 10.00
ZOMETA	1 5.00	1 5.00	0 0.00	0 0.00	1 5.00	1 5.00	1 5.00	0 0.00	0 0.00	1 5.00
RADIATION THERAPY	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
DOCETAXEL AND DOXORUBICIN IN COMBINATION	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
NONE	2 10.00	1 5.00	5 25.00	8 40.00 FGJ	2 10.00	2 10.00	1 5.00	8 40.00 FGJ	9 45.00 FGJ	2 10.00
SIGMA	23	24	20	20	21	21	22	20	20	23

Proportions/Mean: All Columns Tested (5% risk level)



(ROTATION C)

QUESTION 2C4. WHICH REGIMEN OF BIOLOGIC THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC, ER-POSITIVE, HER 2-NEGATIVE (0 BY INNUMOHISTOCHEMISTRY)

ROTATION C									
	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9
AGE	43	43	43	43	43	43	43	43	43
DISEASE SITE	BONE	BONE	LIVER,	LIVER,	BONE	BONE	BONE	LIVER,	LIVER,
AD	NONE	NONE	NONE	NONE	AD CMFA	AD AC	AD AC-T	AD AC	AD AC-T
CLINICAL CONDITION	ASYMP	SITES OF MOD PAIN	ASYMP	VERY ILL	SYMP	ASYMP	ASYMP	VERY ILL	VERY ILL
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
BASE	20	20	20	20	20	20	20	20	20
HERCEPTIN	0	0	2	1	1	0	0	0	0
	0.00	0.00	10.00	5.00	5.00	0.00	0.00	0.00	0.00
AREDIA	1	1	0	0	1	0	0	1	1
	5.00	5.00	0.00	0.00	5.00	0.00	0.00	5.00	5.00
NONE	18	18	17	18	17	19	19	18	18
	90.00	90.00	85.00	90.00	85.00	95.00	95.00	90.00	90.00
DON'T KNOW	1	1	1	1	1	1	1	1	1
	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
SIGMA	20	20	20	20	20	20	20	20	20

Proportions/Means: All Columns Tested (5% risk level)

(ROTATION C)

QUESTION 2C4. WHICH REGIMEN OF BIOLOGIC THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC, ER-POSITIVE, HER 2-NEGATIVE (0 BY INNUMOHISTOCHEMISTRY)

ROTATION C										
	CASE 10	CASE 11	CASE 12	CASE 13	CASE 14	CASE 15	CASE 16	CASE 17	CASE 18	CASE 19
AGE	63	63	63	63	63	63	63	63	63	78
DISEASE SITE	BONE	BONE	LIVER,	LIVER,	BONE	BONE	BONE	LIVER,	LIVER,	BONE
AD	NONE	NONE	NONE	NONE	AD CMF	AD AC	AD AC-T	AD AC	AD AC-T	NONE
CLINICAL CONDITION	ASYMP	MULTI SITES OF MOD PAIN	ASYMP	VERY ILL	ASYMP	ASYMP	ASYMP	VERY ILL	VERY ILL	ASYMP
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)
BASE	20	20	20	20	20	20	20	20	20	20
HERCEPTIN	0 0.00	0 0.00	1 5.00	1 5.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00	1 5.00
AREDDIA	2 10.00	2 10.00	1 5.00	0 0.00	2 10.00	2 10.00	2 10.00	1 5.00	1 5.00	2 10.00
NONE	17 85.00	17 85.00	17 85.00	18 90.00	17 85.00	17 85.00	17 85.00	17 85.00	17 85.00	16 80.00
DON'T KNOW	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00
SIGMA	20	20	20	20	20	20	20	20	20	20

Proportions/Means: All Columns Tested (5% risk level)

(ROTATION C)  
QUESTION 2C5. FOR HOW MANY TOTAL PATIENTS HAVE YOU USED A SECOND AROMATASE INHIBITOR AFTER THE PATIENT HAS RECEIVED  
A FIRST ONE FOR METASTATIC DISEASE?

	TOTAL
BASE	20
NONE	1 5.00
1	1 5.00
2	1 5.00
3	2 10.00
5	3 15.00
6	1 5.00
8	1 5.00
10	4 20.00
12	1 5.00
30	2 10.00
42	1 5.00
60	1 5.00
400	1 5.00
MEAN (INCLUDING NONE)	32.60
STANDARD DEVIATION (INCLUDING NONE)	87.85
STANDARD ERROR (INCLUDING NONE)	19.64
MEDIAN (INCLUDING NONE)	9
MEAN (EXCLUDING NONE)	34.32
STANDARD DEVIATION (EXCLUDING NONE)	89.92
STANDARD ERROR (EXCLUDING NONE)	20.63
MEDIAN (EXCLUDING NONE)	10
TOTAL	652
SIGMA	20

(ROTATION C AND IF "USED A SECOND AROMATASE INHIBITOR FOR AT LEAST ONE PATIENT" IN QUESTION 2C5)  
QUESTION 2C6. WHICH OF THE FOLLOWING AROMATASE INHIBITORS HAVE YOU UTILIZED AS A SECOND AI FOLLOWING THE FIRST?

\* ANASTROZOLE (ARIMIDEX) \*

	TOTAL
BASE	19
YES	9 47.37
NO	10 52.63
SIGMA	19

(ROTATION C AND IF "USED A SECOND AROMATASE INHIBITOR FOR AT LEAST ONE PATIENT" IN QUESTION 2C5)  
QUESTION 2C6. WHICH OF THE FOLLOWING AROMATASE INHIBITORS HAVE YOU UTILIZED AS A SECOND AI FOLLOWING THE FIRST?

\* LETROZOLE (FEMARA) \*

	TOTAL
BASE	19
YES	11 57.89
NO	8 42.11
SIGMA	19

(ROTATION C AND IF "USED A SECOND AROMATASE INHIBITOR FOR AT LEAST ONE PATIENT" IN QUESTION 2C5)  
QUESTION 2C6. WHICH OF THE FOLLOWING AROMATASE INHIBITORS HAVE YOU UTILIZED AS A SECOND AI FOLLOWING THE FIRST?

\* EXEMESTANE (AROMASIN) \*

	TOTAL
BASE	19
YES	13 68.42
NO	6 31.58
SIGMA	19

(ROTATION C AND IF "USED A SECOND AROMATASE INHIBITOR FOR AT LEAST ONE PATIENT" IN QUESTION 2C5)  
QUESTION 2C6. WHICH OF THE FOLLOWING AROMATASE INHIBITORS HAVE YOU UTILIZED AS A SECOND AI FOLLOWING THE FIRST?

	TOTAL
BASE	19
ANASTROZOLE (ARIMIDEX)	9 47.37
LETROZOLE (FEMARA)	11 57.89
EXEMESTANE (AROMASIN)	13 68.42

(ROTATION C)  
QUESTION 2C7. ABOUT HOW MANY TOTAL PATIENTS HAVE YOU TREATED WITH BOTH AN AROMATASE INHIBITOR AND A LH-RH AGONIST OR OTHER FORM OF OVARIAN ABLATION?

	TOTAL
BASE	20
NONE	6 30.00
1	1 5.00
2	5 25.00
5	3 15.00
6	1 5.00
8	1 5.00
10	1 5.00
15	1 5.00
200	1 5.00
MEAN (INCLUDING NONE)	13.25
STANDARD DEVIATION (INCLUDING NONE)	44.13
STANDARD ERROR (INCLUDING NONE)	9.87
MEDIAN (INCLUDING NONE)	2
MEAN (EXCLUDING NONE)	18.93
STANDARD DEVIATION (EXCLUDING NONE)	52.26
STANDARD ERROR (EXCLUDING NONE)	13.97
MEDIAN (EXCLUDING NONE)	5
TOTAL	265
SIGMA	20



(ROTATION D)

QUESTION 2D1. IN THE LAST YEAR, ABOUT HOW MANY WOMEN HAVE YOU EVALUATED AND/OR TREATED WITH METASTATIC BREAST CANCER?

	TOTAL
BASE	20
20	2 10.00
25	1 5.00
30	1 5.00
50	4 20.00
60	3 15.00
75	2 10.00
100	1 5.00
125	1 5.00
150	3 15.00
180	1 5.00
300	1 5.00
MEAN (INCLUDING NONE)	89.00
STANDARD DEVIATION (INCLUDING NONE)	69.39
STANDARD ERROR (INCLUDING NONE)	15.52
MEDIAN (INCLUDING NONE)	60
MEAN (EXCLUDING NONE)	89.00
STANDARD DEVIATION (EXCLUDING NONE)	69.39
STANDARD ERROR (EXCLUDING NONE)	15.52
MEDIAN (EXCLUDING NONE)	60
TOTAL	1780
SIGMA	20

(ROTATION D)

QUESTION 2D1A. ABOUT HOW MANY HAD HER2 STATUS DETERMINED?

	TOTAL
BASE	20
15	1 5.00
20	1 5.00
25	1 5.00
30	1 5.00
35	1 5.00
45	1 5.00
50	5 25.00
55	1 5.00
60	2 10.00
65	1 5.00
75	1 5.00
100	1 5.00
120	1 5.00
125	1 5.00
150	1 5.00
MEAN (INCLUDING NONE)	61.50
STANDARD DEVIATION (INCLUDING NONE)	36.17
STANDARD ERROR (INCLUDING NONE)	8.09
MEDIAN (INCLUDING NONE)	50
MEAN (EXCLUDING NONE)	61.50
STANDARD DEVIATION (EXCLUDING NONE)	36.17
STANDARD ERROR (EXCLUDING NONE)	8.09
MEDIAN (EXCLUDING NONE)	50

(ROTATION D)

QUESTION 2D1A. ABOUT HOW MANY HAD HER2 STATUS DETERMINED?

	TOTAL
BASE	20
TOTAL	1230
SIGMA	20

(ROTATION D AND IF "HAD A PATIENT WITH HER2 STATUS" IN QUESTION Q2D1A)  
QUESTION 2D1B. ABOUT HOW MANY WERE HER2 POSITIVE?

	TOTAL
BASE	20
2	1 5.00
3	2 10.00
5	1 5.00
10	4 20.00
15	3 15.00
20	1 5.00
25	2 10.00
30	4 20.00
40	2 10.00
MEAN (INCLUDING NONE)	18.40
STANDARD DEVIATION (INCLUDING NONE)	12.14
STANDARD ERROR (INCLUDING NONE)	2.71
MEDIAN (INCLUDING NONE)	15
MEAN (EXCLUDING NONE)	18.40
STANDARD DEVIATION (EXCLUDING NONE)	12.14
STANDARD ERROR (EXCLUDING NONE)	2.71
MEDIAN (EXCLUDING NONE)	15
TOTAL	368
SIGMA	20

(ROTATION D)

QUESTION 2D2. WHICH REGIMEN OF CHEMOTHERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC HER 2-POSITIVE

ROTATION D

	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9	CASE 10	CASE 11
AGE	43	43	43	43	43	43	43	43	43	43	63
DISEASE SITE				LIVER, LUNG	LIVER, LUNG	BONE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE
ER	BONE	BONE	BONE	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.
AD	NONE	NONE	NONE	NONE	NONE	AD CMF A	AD AC	AD AC-T	AD AC	AD AC-T	NONE
CLINICAL CONDITION	ASYMP	MULTI SITES OF MOD PAIN	MULTI SITES OF MOD PAIN	ASYMP	VERY ILL	ASYMP	ASYMP	ASYMP	VERY ILL	VERY ILL	ASYMP
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)
BASE	20	20	20	20	20	20	20	20	20	20	20
PACLITAXEL	4 20.00	9 45.00CHJ	3 15.00	9 45.00CHJ	9 45.00CHJ	6 30.00	7 35.00	3 15.00	10 50.00CHJ	3 15.00	5 25.00
DOCETAXEL	4 20.00	4 20.00	3 15.00	5 25.00	5 25.00	6 30.00	5 25.00	6 30.00	6 30.00	9 45.00CK	2 10.00
DOXORUBICIN	2 10.00	2 10.00	1 5.00	1 5.00	2 10.00	2 10.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00
CAPECITABINE	1 5.00	1 5.00	0 0.00	0 0.00	1 5.00	1 5.00	1 5.00	2 10.00	1 5.00	1 5.00	1 5.00
VINORELBINE	1 5.00	2 10.00	1 5.00	2 10.00	2 10.00	1 5.00	1 5.00	3 15.00	2 10.00	7 35.00ACF G	2 10.00
DOCETAXEL AND CAPECITABINE IN COMBINATION	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00	1 5.00	2 10.00	0 0.00	0 0.00
CYTOXAN/ CYCLOPHOSPHAMIDE	1 5.00	1 5.00	1 5.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
CARBOPLATIN	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	0 0.00
CMF - CYTOXAN, METHOTREXATE, 5FU (FLUOROURACIL) IN COMBINATION	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	3 15.00
FAC - 5FU (FLUOROURACIL), ADRIAMYCIN, CYTOXAN IN COMBINATION	1 5.00	1 5.00	0 0.00	1 5.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
CAF - CYCLOPHOSPHAMIDE, ADRIAMYCIN, 5FU (FLUOROURACIL) IN COMBINATION	1 5.00	1 5.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	3 15.00
DOCETAXEL AND EPIRUBICIN IN COMBINATION	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	2 10.00
NONE	5 25.00BEIJ	0 0.00	11 55.00BDEF IJ	1 5.00	0 0.00	3 15.00	5 25.00BEI J	5 25.00BEIJ	0 0.00	0 0.00	7 35.00BDEIJ
DON'T KNOW	0 0.00	0 0.00	0 0.00	2 10.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION D)

QUESTION 2D2. WHICH REGIMEN OF CHEMOTHERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC HER 2-POSITIVE

ROTATION D											
	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9	CASE 10	CASE 11
AGE	43	43	43	43	43	43	43	43	43	43	63
DISEASE SITE	BONE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE
ER	NEG.	NEG.	+	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.
AD	NONE	NONE	NONE	NONE	NONE	AD CMF A	AD AC	AD AC-T	AD AC	AD AC-T	NONE
CLINICAL CONDITION	ASYMP	MULTI SITES OF MOD PAIN	MULTI SITES OF MOD PAIN	ASYMP	VERY ILL	ASYMP	ASYMP	ASYMP	VERY ILL	VERY ILL	ASYMP
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)
BASE	20	20	20	20	20	20	20	20	20	20	20
SIGMA	21	22	22	22	23	22	21	21	22	21	26

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION D)

QUESTION 2D2. WHICH REGIMEN OF CHEMOTHERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC HER 2-POSITIVE

ROTATION D											
	CASE 12	CASE 13	CASE 14	CASE 15	CASE 16	CASE 17	CASE 18	CASE 19	CASE 20	CASE 21	CASE 22
AGE	63	63	63	63	63	63	63	63	63	78	78
DISEASE SITE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE	BONE
ER	NEG.	+	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.	+
AD	NONE	NONE	NONE	NONE	AD CMF	AD AC	AD AC-T	AD AC	AD ACT	NONE	NONE
CLINICAL CONDITION	MULTI SITES OF MOD PAIN	MULTI SITES OF MOD PAIN	ASYMP	VERY ILL	ASYMP	ASYMP	ASYMP	VERY ILL	VERY ILL	ASYMP	ASYMP
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)
BASE	20	20	20	20	20	20	20	20	20	20	20
PACLITAXEL	9 45.00BG K	2 10.00	7 35.00IK	9 45.00BGI JK	6 30.00IK	8 40.00BGI K	2 10.00	8 40.00BGI	1 5.00	3 15.00	0 0.00
DOCETAXEL	5 25.00K	3 15.00	5 25.00K	5 25.00K	3 15.00	4 20.00K	6 30.00JK	8 40.00JK	9 45.00BEJK	1 5.00	0 0.00
DOXORUBICIN	3 15.00	2 10.00	3 15.00	1 5.00	2 10.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
CAPECITABINE	1 5.00	0 0.00	0 0.00	1 5.00	1 5.00	1 5.00	3 15.00	0 0.00	2 10.00	3 15.00	0 0.00
VINORELBINE	2 10.00	2 10.00	2 10.00	3 15.00	2 10.00	1 5.00	2 10.00	2 10.00	6 30.00FJK	0 0.00	0 0.00
GEMCITABINE	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	1 5.00	0 0.00	0 0.00
DOCETAXEL AND CAPECITABINE IN COMBINATION	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00
CARBOPLATIN	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	1 5.00	0 0.00	0 0.00
CMF - CYTOXAN, METHOTREXATE, 5FU (FLUOROURACIL) IN COMBINATION	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00
FAC - 5FU (FLUOROURACIL), ADRIAMYCIN, CYTOXAN IN COMBINATION	1 5.00	0 0.00	1 5.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00
DOCETAXEL AND EPIRUBICIN IN COMBINATION	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
NONE	0 0.00	11 55.00ACD I	2 10.00	1 5.00	6 30.00ADH I	5 25.00AHI	7 35.00ADHI	0 0.00	0 0.00	9 45.00AC DHI	20 100.00ABCDEF GHIJ
DON'T KNOW	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00	2 10.00	0 0.00
SIGMA	22	22	22	23	21	21	22	21	21	20	20

Proportions/Means: All Columns Tested (5% risk level)

(ROTATION D)

QUESTION 2D3. WHICH REGIMEN OF ENDOCRINE THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC HER 2-POSITIVE

ROTATION D											
	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9	CASE 10	CASE 11
AGE	43	43	43	43	43	43	43	43	43	43	63
DISEASE SITE				LIVER,	LIVER,				LIVER,	LIVER,	
ER	BONE	BONE	BONE	LUNG	LUNG	BONE	BONE	BONE	LUNG	LUNG	BONE
AD	NEG.	NEG.	+	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.
CLINICAL CONDITION	NONE	NONE	NONE	NONE	NONE	AD CMF A	AD AC	AD AC-T	AD AC	AD AC-T	NONE
	ASYMP	MULTI SITES OF MOD PAIN	MULTI SITES OF MOD PAIN	ASYMP	VERY ILL	ASYMP	ASYMP	ASYMP	VERY ILL	VERY ILL	ASYMP
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)
BASE	20	20	20	20	20	20	20	20	20	20	20
TAMOXIFEN (NOLVADEX)	0	0	1	0	0	0	0	0	0	0	0
	0.00	0.00	5.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ANASTROZOLE (ARIMIDEX)	1	0	5	1	0	0	0	0	0	0	1
	5.00	0.00	25.00	5.00	0.00	0.00	0.00	0.00	0.00	0.00	5.00
			BEFGHIJ								
LETROZOLE (FEMARA)	0	0	4	0	0	0	0	0	0	0	0
	0.00	0.00	20.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
			ABDEFGHIJK								
LH-RH AGONIST/SURGICAL OR RADIATION OVARIAN ABLATION	1	0	3	0	0	0	0	0	0	0	0
	5.00	0.00	15.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
TAMOXIFEN AND LH-RH AGONIST	0	0	1	0	0	0	0	0	0	0	0
	0.00	0.00	5.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
ANASTROZOLE AND LH-RH AGONIST/ SURGICAL OR RADIATION OVARIAN ABLATION	0	0	1	0	0	0	0	0	0	0	0
	0.00	0.00	5.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NONE	19	20	5	19	20	20	20	20	20	20	19
	95.00C	100.00C	25.00	95.00C	100.00C	100.00C	100.00C	100.00C	100.00C	100.00C	95.00C
SIGMA	21	20	20	20	20	20	20	20	20	20	20

Proportions/Mean: All Columns Tested (5% risk level)



(ROTATION D)

QUESTION 2D3. WHICH REGIMEN OF ENDOCRINE THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC HER 2-POSITIVE

ROTATION D											
	CASE 12	CASE 13	CASE 14	CASE 15	CASE 16	CASE 17	CASE 18	CASE 19	CASE 20	CASE 21	CASE 22
AGE	63	63	63	63	63	63	63	63	63	78	78
DISEASE SITE			LIVER,	LIVER,				LIVER,	LIVER,		
ER	BONE	BONE	LUNG	LUNG	BONE	BONE	BONE	LUNG	LUNG	BONE	BONE
AD	NEG.	+	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.	+
CLINICAL CONDITION	NONE	NONE	NONE	NONE	AD CMF	AD AC	AD AC-T	AD AC	AD ACT	NONE	NONE
	MULTI	MULTI		VERY				VERY	VERY		
	SITES OF MOD PAIN	SITES OF MOD PAIN	ASYMP	ILL	ASYMP	ASYMP	ASYMP	ILL	ILL	ASYMP	ASYMP
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)
BASE	20	20	20	20	20	20	20	20	20	20	20
TAMOXIFEN (NOLVADEX)	0	1	0	0	0	0	0	0	0	0	1
	0.00	5.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.00
ANASTROZOLE (ARIMIDEX)	0	9	1	0	0	0	0	0	0	0	10
	0.00	45.00ACDEF	5.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	50.00ACDEFGHIJ
		GHIJ									
LETROZOLE (FEMARA)	0	6	0	0	0	0	0	0	0	0	8
	0.00	30.00ACDEF	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	40.00ACDEFGHIJ
		GHIJ									
EXEMESTANE (AROMASIN)	0	0	0	0	0	0	0	0	0	0	1
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.00
NONE	20	4	19	20	20	20	20	20	20	20	0
	100.00BK	20.00K	95.00BK	100.00BK	100.00BK	100.00BK	100.00BK	100.00BK	100.00BK	100.00BK	0.00
SIGMA	20	20	20	20	20	20	20	20	20	20	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION D)

QUESTION 2D4. WHICH REGIMEN OF BIOLOGIC THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC HER 2-POSITIVE

ROTATION D											
	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9	CASE 10	CASE 11
AGE	43	43	43	43	43	43	43	43	43	43	63
DISEASE SITE				LIVER,	LIVER,				LIVER,	LIVER,	
ER	BONE	BONE	BONE	LUNG	LUNG	BONE	BONE	BONE	LUNG	LUNG	BONE
AD	NEG.	NEG.	+	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.
AD	NONE	NONE	NONE	NONE	NONE	AD CMF A	AD AC	AD AC-T	AD AC	AD AC-T	NONE
CLINICAL		MULTI	MULTI		VERY				VERY	VERY	
CONDITION	ASYMP	SITES OF	SITES OF	ASYMP	ILL	ASYMP	ASYMP	ASYMP	ILL	ILL	ASYMP
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)
BASE	20	20	20	20	20	20	20	20	20	20	20
HERCEPTIN	13 65.00	14 70.00C	7 35.00	15 75.00C	15 75.00C	12 60.00	13 65.00	14 70.00C	16 80.00C	17 85.00CK	10 50.00
ARELIA	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00	1 5.00	0 0.00	0 0.00	1 5.00
NONE	6 30.00	6 30.00	13 65.00ABD EGHIJ	4 20.00	4 20.00	7 35.00	6 30.00	5 25.00	4 20.00	3 15.00	9 45.00J
DON'T KNOW	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
SIGMA	20	20	20	20	20	20	20	20	20	20	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION D)

QUESTION 2D4. WHICH REGIMEN OF BIOLOGIC THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC HER 2-POSITIVE

ROTATION D											
	CASE 12	CASE 13	CASE 14	CASE 15	CASE 16	CASE 17	CASE 18	CASE 19	CASE 20	CASE 21	CASE 22
AGE	63	63	63	63	63	63	63	63	63	78	78
DISEASE SITE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE	BONE
ER	NEG.	+	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.	NEG.	+
AD	NONE	NONE	NONE	NONE	AD CMF	AD AC	AD AC-T	AD AC	AD ACT	NONE	NONE
CLINICAL CONDITION	MULTI SITES OF MOD PAIN	MULTI SITES OF MOD PAIN	ASYMP	VERY ILL	ASYMP	ASYMP	ASYMP	VERY ILL	VERY ILL	ASYMP	ASYMP
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)
BASE	20	20	20	20	20	20	20	20	20	20	20
HERCEPTIN	14 70.00K	8 40.00	14 70.00K	15 75.00BK	13 65.00K	13 65.00K	14 70.00K	15 75.00BK	16 80.00BK	13 65.00K	4 20.00
AREDIA	0 0.00	1 5.00	0 0.00	0 0.00	1 5.00	1 5.00	1 5.00	1 5.00	0 0.00	2 10.00	1 5.00
NONE	6 30.00	11 55.00HI	6 30.00	5 25.00	6 30.00	6 30.00	5 25.00	4 20.00	4 20.00	6 30.00	15 75.00ACDEFGHIJ
SIGMA	20	20	20	20	20	20	20	20	20	21	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION D)

QUESTION 2D5. WHICH OF THE FOLLOWING STATEMENTS BEST DESCRIBES YOUR USE OF TAXOL THERAPY FOR THIS PATIENT?

	TOTAL
BASE	20
CONTINUE UNTIL PROGRESSION	13
	65.00
STOP BEFORE PROGRESSION	7
	35.00
SIGMA	20

(ROTATION D)

QUESTION 2D6. WHICH STATEMENT BEST DESCRIBES YOUR USE OF HERCEPTIN FOR THIS PATIENT?

	TOTAL
BASE	20
CONTINUE AFTER PROGRESSION AND ADD ANOTHER CHEMO AGENT	8 40.00
CONTINUE INDEFINITELY AS LONG AS PATIENT WAS DOING WELL CLINICALLY AND ADD MULTIPLE CHEMO AGENTS	6 30.00
CONTINUE UNTIL PROGRESSION, THEN STOP	4 20.00
STOP BEFORE PROGRESSION	2 10.00
SIGMA	20

(ROTATION D)

QUESTION 2D7. NOW ASSUME THAT YOU ARE PRESENTED WITH A PATIENT THAT IS 57 YEAR OLD WHO HAS HER2 POSITIVE BREAST CANCER AND ON FIRST RELAPSE IS TREATED WITH HERCEPTIN. AFTER 4 MONTHS, SHE HAS HAD A GOOD RESPONSE AND IS DOING WELL. WHICH OF THE FOLLOWING STATEMENTS BEST DESCRIBES GENERALLY HOW LONG YOU WOULD CONTINUE THERAPY FOR THIS PATIENT?

	TOTAL
BASE	20
CONTINUE AFTER PROGRESSION, THEN ADD CHEMO AGENT AND CONTINUE	13 65.00
CONTINUE UNTIL PROGRESSION, THEN STOP	5 25.00
STOP BEFORE PROGRESSION	2 10.00
SIGMA	20

(ROTATION D)

QUESTION 2D8. WHAT PERCENTAGE OF YOUR PATIENTS WITH METASTATIC BREAST CANCER DO YOU ATTEMPT TO DEFINE HER2 STATUS?

	TOTAL
BASE	20
71 - 80 %	2 10.00
81 - 90 %	3 15.00
91 - 99 %	1 5.00
100 %	14 70.00
MEAN (INCLUDING NONE)	95.75
STANDARD DEVIATION (INCLUDING NONE)	7.66
STANDARD ERROR (INCLUDING NONE)	1.71
MEDIAN (INCLUDING NONE)	100
MEAN (EXCLUDING NONE)	95.75
STANDARD DEVIATION (EXCLUDING NONE)	7.66
STANDARD ERROR (EXCLUDING NONE)	1.71
MEDIAN (EXCLUDING NONE)	100
SIGMA	20

(ROTATION D)

QUESTION 2D9. WHAT PERCENTAGE OF YOUR PATIENTS WITH PRIMARY BREAST CANCER DO YOU ATTEMPT TO DEFINE HER2 STATUS?

	TOTAL
BASE	20
NONE	2
	10.00
1 - 10 %	1
	5.00
41 - 50 %	1
	5.00
91 - 99 %	1
	5.00
100 %	15
	75.00
MEAN (INCLUDING NONE)	82.75
STANDARD DEVIATION (INCLUDING NONE)	36.04
STANDARD ERROR (INCLUDING NONE)	8.06
MEDIAN (INCLUDING NONE)	100
MEAN (EXCLUDING NONE)	91.94
STANDARD DEVIATION (EXCLUDING NONE)	23.59
STANDARD ERROR (EXCLUDING NONE)	5.56
MEDIAN (EXCLUDING NONE)	100
SIGMA	20



(ROTATION D)

QUESTION 2D10. WITH WHICH OF THE FOLLOWING DO YOU DETERMINE IF A PATIENT IS HER2 POSITIVE?

\* IHC (HERCEPT TEST) 3+ \*

	TOTAL
BASE	20
YES	18 90.00
NO	1 5.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION D)

QUESTION 2D10. WITH WHICH OF THE FOLLOWING DO YOU DETERMINE IF A PATIENT IS HER2 POSITIVE?

\* IHC (HERCEPT TEST) 2+ \*

	TOTAL
BASE	20
YES	8 40.00
NO	11 55.00
DON'T KNOW	1 5.00
SIGMA	20

(ROTATION D)

QUESTION 2D10. WITH WHICH OF THE FOLLOWING DO YOU DETERMINE IF A PATIENT IS HER2 POSITIVE?

\* IHC (HERCEPT TEST) 1+ \*

	TOTAL
BASE	20
NO	18 90.00
DON'T KNOW	2 10.00
SIGMA	20

(ROTATION D)

QUESTION 2D10. WITH WHICH OF THE FOLLOWING DO YOU DETERMINE IF A PATIENT IS HER2 POSITIVE?

\* FISH POSITIVE \*

	TOTAL
BASE	20
YES	19 95.00
NO	1 5.00
SIGMA	20

(ROTATION D)

QUESTION 2D10. IS THERE SOME OTHER WAY THAT I HAVEN'T MENTIONED?

	TOTAL
BASE	20
YES	1 5.00
NO	19 95.00

(ROTATION D AND IF "SOME OTHER WAY TO DETERMINE IF PATIENT IS HER2 POSITIVE" IN QUESTION 2D10)  
QUESTION 2D10. OTHER MENTIONS

	TOTAL
BASE	1
IHC 2+ OR 3+, CONFIRMED BY	1
FISH	100.00

(ROTATION D)

QUESTION 2D10. WITH WHICH OF THE FOLLOWING DO YOU DETERMINE IF A PATIENT IS HER2 POSITIVE?

	TOTAL
BASE	20
FISH POSITIVE	19 95.00
IHC (HERCEPT TEST) 3+	18 90.00
IHC (HERCEPT TEST) 2+	8 40.00
IHC 2+ OR 3+, CONFIRMED BY FISH	1 5.00

(ROTATION D)

QUESTION 2D11. WHICH OF THE FOLLOWING BEST DESCRIBES HOW OFTEN YOU OBTAIN FISH RESULTS ON A PATIENT YOU ARE TREATING?

	TOTAL
BASE	20
COMMONLY	7 35.00
OCCASIONALLY	10 50.00
RARELY	2 10.00
HAVE NOT DONE IT	1 5.00
SIGMA	20



(IF "COMMONLY, OCCASIONALLY OR RARELY OBTAIN FISH RESULTS" IN QUESTION 2D11)  
QUESTION 2D12. HOW MANY PATIENTS HAVE YOU ASKED A LAB TO DO FISH TESTING?

	TOTAL
BASE	19
1	1 5.26
3	1 5.26
5	1 5.26
7	2 10.53
10	1 5.26
12	1 5.26
15	2 10.53
20	4 21.05
25	1 5.26
30	2 10.53
50	2 10.53
DON'T KNOW/REFUSED	1 5.26
MEAN (INCLUDING NONE)	18.89
STANDARD DEVIATION (INCLUDING NONE)	14.20
STANDARD ERROR (INCLUDING NONE)	3.35
MEDIAN (INCLUDING NONE)	18
MEAN (EXCLUDING NONE)	18.89
STANDARD DEVIATION (EXCLUDING NONE)	14.20
STANDARD ERROR (EXCLUDING NONE)	3.35
MEDIAN (EXCLUDING NONE)	18
TOTAL	340
SIGMA	19

(ROTATION D)

QUESTION 2D13. WHICH OF THE FOLLOWING BEST DESCRIBES TO WHAT EXTENT YOU ARE USUALLY CONCERNED ABOUT CARDIOTOXICITY WHEN CONSIDERING THE USE OF HERCEPTIN AS THERAPY IN METASTATIC DISEASE?

	TOTAL
BASE	20
OFTEN A MAJOR CONCERN	3 15.00
OCCASIONALLY A CONCERN	12 60.00
USUALLY NOT A MAJOR CONCERN	5 25.00
SIGMA	20

(ROTATION D)

QUESTION 2D14. DO YOU ROUTINELY UTILIZE REGULAR CARDIAC MONITORING IN WOMEN TREATED WITH HERCEPTIN AS THERAPY IN METASTATIC DISEASE?

	TOTAL
BASE	20
YES	12 60.00
NO	8 40.00
SIGMA	20

(IF "UTILIZE CARDIAC MONITORING IN WOMEN TREATED WITH HERCEPTIN" IN QUESTION 2D14)  
QUESTION 2D14A. WHAT TYPE OF TESTS DO YOU USE?

	TOTAL
BASE	12
MUGA SCAN	12
	100.00
EKG	3
	25.00
NUCLEAR MEDICINE	1
	8.33
STRESS TEST	1
	8.33
SIGMA	17

(IF "UTILIZE CARDIAC MONITORING IN WOMEN TREATED WITH HERCEPTIN" IN QUESTION 2D14)

QUESTION 2D14B. AT WHAT INTERVALS DO YOU HAVE THESE TESTS ADMINISTERED?

	TOTAL
BASE	12
EVERY 6 MONTHS	3
	25.00
EVERY 3-6 MONTHS	3
	25.00
WHEN PATIENT DEVELOPS SYMPTOMS	1
	8.33
EVERY 4 MONTHS	1
	8.33
EVERY 4-6 MONTHS WHILE ON THERAPY	1
	8.33
EVERY 3 MONTHS	1
	8.33
ONCE A YEAR	1
	8.33
BEFORE TREATMENT, THEN EVERY 4-6 MONTHS	1
	8.33
BEFORE TREATMENT	1
	8.33
EVERY 2-3 CYCLES	1
	8.33
SIGMA	14

(ROTATION E)  
 QUESTION 2E2. WHICH REGIMEN OF CHEMOTHERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC, ER-NEGATIVE, HER 2-NEGATIVE

ROTATION E										
	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9	
AGE	43	43	43	43	43	43	43	43	43	43
DISEASE SITE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	
AD	NONE	NONE	NONE	NONE	AD CMF A	AD AC	AD AC-T	AD AC	AD AC-T	
CLINICAL CONDITION	ASYMP	MULTI SITES OF MOD PAIN	ASYMP	VERY ILL	SYMP	ASYMP	ASYMP	VERY ILL	VERY ILL	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	
BASE	20	20	20	20	20	20	20	20	20	
PACLITAXEL	3 15.00	4 20.00	3 15.00	1 5.00	2 10.00	3 15.00	2 10.00	2 10.00	1 5.00	
DOCETAXEL	6 30.00	10 50.00	10 50.00	9 45.00	15 75.00	12 60.00	6 30.00	9 45.00	5 25.00	
DOXORUBICIN	3 15.00	3 15.00	3 15.00	5 25.00	3 15.00	0 0.00	0 0.00	1 5.00	1 5.00	
EPIRUBICIN	0 0.00	0 0.00	0 0.00	2 10.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	
CAPECITABINE	0 0.00	3 15.00	1 5.00	2 10.00	3 15.00	4 20.00	4 20.00	5 25.00	5 25.00	
VINORELBINE	3 15.00	1 5.00	3 15.00	2 10.00	2 10.00	3 15.00	8 40.00	5 25.00	8 40.00	
GEMCITABINE	0 0.00	0 0.00	0 0.00	2 10.00	1 5.00	2 10.00	2 10.00	2 10.00	4 20.00	
DOCETAXEL AND DOXORUBICIN IN COMBINATION	1 5.00	1 5.00	1 5.00	3 15.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00	
CYTOXAN/ CYCLOPHOSPHAMIDE	1 5.00	1 5.00	1 5.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	
CARBOPLATIN	0 0.00	0 0.00	1 5.00	1 5.00	1 5.00	1 5.00	0 0.00	1 5.00	1 5.00	
VINORELBINE AND GEMCITABINE IN COMBINATION	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	2 10.00	
DOXORUBICIN AND CYCLOPHOSPHAMIDE IN COMBINATION	0 0.00	1 5.00	1 5.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	
AC - ADRIAMYCIN AND CYTOXAN IN COMBINATION	1 5.00	1 5.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	
TAXOTERE AND ADRIAMYCIN IN COMBINATION	0 0.00	0 0.00	1 5.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	
DOXORUBICIN AND CYTOXAN IN COMBINATION	1 5.00	1 5.00	1 5.00	0 0.00	1 5.00	1 5.00	1 5.00	0 0.00	0 0.00	
PACLITAXEL AND DOXORUBICIN IN COMBINATION	0 0.00	0 0.00	1 5.00	1 5.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00	

(ROTATION E)  
 QUESTION 2E2. WHICH REGIMEN OF CHEMOTHERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC, ER-NEGATIVE, HER 2-NEGATIVE

ROTATION E									
	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9
AGE	43	43	43	43	43	43	43	43	43
DISEASE SITE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE	BONE	BONE	LIVER, LUNG	LIVER, LUNG
AD	NONE	NONE	NONE	NONE	AD CMF A	AD AC	AD AC-T	AD AC	AD AC-T
CLINICAL CONDITION	ASYMP	MULTI SITES OF MOD PAIN	ASYMP	VERY ILL	SYMP	ASYMP	ASYMP	VERY ILL	VERY ILL
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
BASE	20	20	20	20	20	20	20	20	20
NONE	4	2	1	1	0	1	2	0	0
	20.00EHI	10.00	5.00	5.00	0.00	5.00	10.00	0.00	0.00
SIGMA	23	28	29	32	28	27	25	27	29

Proportions/Means: All Columns Tested (5% risk level)

(ROTATION E)

QUESTION 2E2. WHICH REGIMEN OF CHEMOTHERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC, ER-NEGATIVE, HER 2-NEGATIVE

ROTATION E										
	CASE 10	CASE 11	CASE 12	CASE 13	CASE 14	CASE 15	CASE 16	CASE 17	CASE 18	CASE 19
AGE	63	63	63	63	63	63	63	63	63	78
DISEASE SITE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE
AD	NONE	NONE	NONE	NONE	AD CMF	AD AC	AD AC-T	AD AC	AD AC-T	NONE
CLINICAL CONDITION	ASYMP	MULTI SITES OF MOD PAIN	ASYMP	VERY ILL	ASYMP	ASYMP	ASYMP	VERY ILL	VERY ILL	ASYMP
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)
BASE	20	20	20	20	20	20	20	20	20	20
PACLITAXEL	3 15.00	3 15.00	4 20.00J	2 10.00	5 25.00J	5 25.00J	2 10.00	2 10.00	1 5.00	0 0.00
DOCETAXEL	6 30.00	12 60.00	10 50.00	9 45.00	7 35.00	9 45.00	7 35.00	11 55.00	8 40.00	6 30.00
DOXORUBICIN	3 15.00	3 15.00	3 15.00	4 20.00FJ	3 15.00	0 0.00	1 5.00	2 10.00	1 5.00	0 0.00
EPIRUBICIN	0 0.00	1 5.00	0 0.00	0 0.00	1 5.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00
CAPECITABINE	0 0.00	1 5.00	1 5.00	2 10.00	0 0.00	1 5.00	2 10.00	4 20.00AE	5 25.00AE	3 15.00
VINORELBINE	3 15.00	2 10.00	3 15.00	4 20.00	3 15.00	4 20.00	6 30.00	4 20.00	6 30.00	4 20.00
GEMCITABINE	0 0.00	0 0.00	0 0.00	2 10.00	1 5.00	1 5.00	1 5.00	2 10.00	4 20.00ABCJ	0 0.00
DOCETAXEL AND DOXORUBICIN IN COMBINATION	0 0.00	1 5.00	2 10.00	4 20.00AEFG J	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00	0 0.00
CYTOXAN/ CYCLOPHOSPHAMIDE	0 0.00	1 5.00	1 5.00	1 5.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
CARBOPLATIN	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	1 5.00	0 0.00
VINORELBINE AND GEMCITABINE IN COMBINATION	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00
DOXORUBICIN AND CYCLOPHOSPHADMIDE IN COMBINATION	0 0.00	1 5.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
AC - ADRIAMYCIN AND CYTOXAN IN COMBINATION	1 5.00	0 0.00	1 5.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
NAVELBINE	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	1 5.00	1 5.00	0 0.00	0 0.00	0 0.00
ADRIAMYCIN AND DOCETAXEL IN COMBINATION	0 0.00	0 0.00	1 5.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00

Proportions/Mean: All Columns Tested (5% risk level)



(ROTATION E)

QUESTION 2E2. WHICH REGIMEN OF CHEMOTHERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC, ER-NEGATIVE, HER 2-NEGATIVE

ROTATION E										
	CASE 10	CASE 11	CASE 12	CASE 13	CASE 14	CASE 15	CASE 16	CASE 17	CASE 18	CASE 19
AGE	63	63	63	63	63	63	63	63	63	78
DISEASE SITE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE
AD	NONE	NONE	NONE	NONE	AD CMF	AD AC	AD AC-T	AD AC	AD AC-T	NONE
CLINICAL CONDITION	ASYMP	MULTI SITES OF MOD PAIN	ASYMP	VERY ILL	ASYMP	ASYMP	ASYMP	VERY ILL	VERY ILL	ASYMP
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)
BASE	20	20	20	20	20	20	20	20	20	20
DOXORUBICIN AND CYTOXAN IN COMBINATION	1 5.00	1 5.00	1 5.00	1 5.00	2 10.00	1 5.00	1 5.00	0 0.00	0 0.00	0 0.00
PACLITAXEL AND DOXORUBICIN IN COMBINATION	0 0.00	1 5.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
NONE	5 25.00	0 BCDHI	0 0.00	0 0.00	1 5.00	2 10.00	3 15.00	0 0.00	0 0.00	9 45.00
DON'T KNOW	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
SIGMA	23	27	29	31	25	24	25	27	28	22

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION E)

QUESTION 2E3. WHICH REGIMEN OF ENDOCRINE THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC, ER-NEGATIVE, HER 2-NEGATIVE

ROTATION E									
	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9
AGE	43	43	43	43	43	43	43	43	43
DISEASE SITE			LIVER, LUNG	LIVER, LUNG				LIVER, LUNG	LIVER, LUNG
AD	BONE NONE	BONE NONE	NONE	NONE	BONE AD CMF A	BONE AD AC	BONE AD AC-T	LUNG AD AC	LUNG AD AC-T
CLINICAL CONDITION	ASYMP	MULTI SITES OF MOD PAIN	ASYMP	VERY ILL	SYMP	ASYMP	ASYMP	VERY ILL	VERY ILL
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)
BASE	20	20	20	20	20	20	20	20	20
ANASTROZOLE (ARIMIDEX)	1 5.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00
LH-RH AGONIST/SURGICAL OR RADIATION OVARIAN ABLATION	1 5.00	1 5.00	1 5.00	1 5.00	0 0.00	1 5.00	1 5.00	0 0.00	0 0.00
AREDIA	3 15.00	3 15.00	0 0.00	0 0.00	2 10.00	2 10.00	2 10.00	0 0.00	0 0.00
NONE	17 85.00	17 85.00	19 95.00	19 95.00	18 90.00	18 90.00	18 90.00	20 100.00	20 100.00
DON'T KNOW	0 0.00	0 0.00	0 0.00	0 0.00	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00
SIGMA	22	22	20	20	21	21	21	20	20

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION E)

QUESTION 2E3. WHICH REGIMEN OF ENDOCRINE THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC, ER-NEGATIVE, HER 2-NEGATIVE

ROTATION E										
	CASE 10	CASE 11	CASE 12	CASE 13	CASE 14	CASE 15	CASE 16	CASE 17	CASE 18	CASE 19
AGE	63	63	63	63	63	63	63	63	63	78
DISEASE SITE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE
AD	NONE	NONE	NONE	NONE	AD CMF	AD AC	AD AC-T	AD AC	AD AC-T	NONE
CLINICAL CONDITION	ASYMP	MULTI SITES OF MOD PAIN	ASYMP	VERY ILL	ASYMP	ASYMP	ASYMP	VERY ILL	VERY ILL	ASYMP
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)
BASE	20	20	20	20	20	20	20	20	20	20
ANASTROZOLE (ARIMIDEX)	1 5.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	0 0.00	2 10.00
AREDIA	2 10.00	2 10.00	1 5.00	0 0.00	2 10.00	2 10.00	2 10.00	0 0.00	0 0.00	2 10.00
NONE	18 90.00	19 95.00	20 100.00	20 100.00	19 95.00	19 95.00	19 95.00	20 100.00	20 100.00	17 85.00
SIGMA	21	21	21	20	21	21	21	20	20	21

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION E)

QUESTION 2E4. WHICH REGIMEN OF BIOLOGIC THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC, ER-NEGATIVE, HER 2-NEGATIVE

ROTATION E										
	CASE 1	CASE 2	CASE 3	CASE 4	CASE 5	CASE 6	CASE 7	CASE 8	CASE 9	
AGE	43	43	43	43	43	43	43	43	43	43
DISEASE SITE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	
AD	NONE	NONE	NONE	NONE	AD CMF A	AD AC	AD AC-T	AD AC	AD AC-T	
CLINICAL CONDITION	ASYMP	MULTI SITES OF MOD PAIN	ASYMP	VERY ILL	SYMP	ASYMP	ASYMP	VERY ILL	VERY ILL	
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	
BASE	20	20	20	20	20	20	20	20	20	
OTHER	1 5.00	1 5.00	0 0.00	0 0.00	1 5.00	1 5.00	1 5.00	0 0.00	0 0.00	
AREDIA	3 15.00	3 15.00	0 0.00	0 0.00	2 10.00	2 10.00	2 10.00	0 0.00	0 0.00	
NONE	19 95.00	19 95.00	20 100.00	20 100.00	19 95.00	19 95.00	19 95.00	20 100.00	20 100.00	
SIGMA	23	23	20	20	22	22	22	20	20	

Proportions/Mean: All Columns Tested (5% risk level)

(ROTATION E)

QUESTION 2E4. WHICH REGIMEN OF BIOLOGIC THERAPY WOULD YOU PRESCRIBE FOR SCENARIO 1?

\* CLINICAL SCENARIO \*  
 METASTATIC, ER-NEGATIVE, HER 2-NEGATIVE

ROTATION E										
	CASE 10	CASE 11	CASE 12	CASE 13	CASE 14	CASE 15	CASE 16	CASE 17	CASE 18	CASE 19
AGE	63	63	63	63	63	63	63	63	63	78
DISEASE SITE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE	BONE	BONE	LIVER, LUNG	LIVER, LUNG	BONE
AD	NONE	NONE	NONE	NONE	AD CMF	AD AC	AD AC-T	AD AC	AD AC-T	NONE
CLINICAL CONDITION	ASYMP	MULTI SITES OF MOD PAIN	ASYMP	VERY ILL	ASYMP	ASYMP	ASYMP	VERY ILL	VERY ILL	ASYMP
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)
BASE	20	20	20	20	20	20	20	20	20	20
OTHER	1 5.00	1 5.00	0 0.00	0 0.00	1 5.00	0 0.00	1 5.00	1 5.00	0 0.00	1 5.00
AREDIA	2 10.00	2 10.00	0 0.00	0 0.00	2 10.00	1 5.00	2 10.00	1 5.00	0 0.00	2 10.00
NONE	19 95.00	19 95.00	20 100.00	20 100.00	19 95.00	20 100.00	19 95.00	19 95.00	20 100.00	19 95.00
SIGMA	22	22	20	20	22	21	22	21	20	22

Proportions/Mean: All Columns Tested (5% risk level)

QUESTION 6. HOW MANY BREAST CANCER PATIENTS DO YOU PERSONALLY SEE IN YOUR OFFICE PER MONTH?

	TOTAL
BASE	100
5	1 1.00
8	1 1.00
10	3 3.00
11	1 1.00
12	3 3.00
15	2 2.00
20	6 6.00
25	4 4.00
30	8 8.00
35	1 1.00
40	12 12.00
45	2 2.00
50	13 13.00
55	1 1.00
60	6 6.00
65	2 2.00
70	3 3.00
75	4 4.00
80	5 5.00
90	1 1.00
100	9 9.00
120	2 2.00

QUESTION 6. HOW MANY BREAST CANCER PATIENTS DO YOU PERSONALLY SEE IN YOUR OFFICE PER MONTH?

	TOTAL
BASE	100
125	1 1.00
130	1 1.00
150	4 4.00
175	1 1.00
200	2 2.00
300	1 1.00
MEAN (INCLUDING NONE)	62.50
STANDARD DEVIATION (INCLUDING NONE)	48.43
STANDARD ERROR (INCLUDING NONE)	4.84
MEDIAN (INCLUDING NONE)	50
MEAN (EXCLUDING NONE)	62.50
STANDARD DEVIATION (EXCLUDING NONE)	48.43
STANDARD ERROR (EXCLUDING NONE)	4.84
MEDIAN (EXCLUDING NONE)	50
TOTAL	6250
SIGMA	100

QUESTION 7. IS YOUR HOSPITAL AFFILIATED WITH A UNIVERSITY HOSPITAL?

	TOTAL
BASE	100
YES	13 13.00
NO	87 87.00
SIGMA	100



	TOTAL
BASE	100
35	2 2.00
39	2 2.00
40	2 2.00
41	6 6.00
42	2 2.00
43	2 2.00
44	3 3.00
45	4 4.00
46	3 3.00
47	3 3.00
48	5 5.00
49	8 8.00
50	4 4.00
51	3 3.00
52	3 3.00
53	8 8.00
54	5 5.00
55	4 4.00
56	8 8.00
57	3 3.00
58	4 4.00
59	2 2.00

	TOTAL
BASE	100
60	2 2.00
62	3 3.00
64	1 1.00
65	1 1.00
66	1 1.00
67	1 1.00
70	1 1.00
DON'T KNOW/REFUSED	4 4.00
MEAN	51.01
STANDARD DEVIATION	7.21
STANDARD ERROR	0.74
MEDIAN	51
TOTAL	4897
SIGMA	100

	TOTAL
BASE	100
MALE	88 88.00
FEMALE	12 12.00
SIGMA	100